# Patent

## Title
Polypeptides having cellulase activity

## Abstract

The present disclosure relates to CBH II chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
The application claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. Nos. 61/166,993, filed, Apr. 6, 2009, and 61/177,882, filed May 13, 2009, the disclosures of which are incorporated herein by reference.


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
The U.S. Government has certain rights in this invention pursuant to Grant No. GM068664 awarded by the National Institutes of Health and Grant No. DAAD19-03-0D-0004 awarded by ARO—US Army Robert Morris Acquisition Center.


TECHNICAL FIELD
The disclosure relates to biomolecular engineering and design, and engineered proteins and nucleic acids.
BACKGROUND
The performance of cellulase mixtures in biomass conversion processes depends on many enzyme properties including stability, product inhibition, synergy among different cellulase components, productive binding versus nonproductive adsorption and pH dependence, in addition to the cellulose substrate physical state and composition. Given the multivariate nature of cellulose hydrolysis, it is desirable to have diverse cellulases to choose from in order to optimize enzyme formulations for different applications and feedstocks.
SUMMARY
The disclosure provides recombinant polypeptides having cellulase activity and increased thermostability and activity compared to a wild-type protein. The disclosure provides and demonstrates that CBHII chimeras and the native enzymes having a Cys to Ser mutation at the C-terminal end (e.g., at about amino acid 310-315 depending upon the native protein sequence, see, e.g., SEQ ID NO:2 and 4) hydrolyze more solid cellulose than the native enzyme in long time hydrolysis assays.
The disclosure provides a recombinant polypeptide comprising a C→S substitution in the C-terminal region in a motif comprising the sequence GECDG (SEQ ID NO:2 from 312-316), wherein the variant comprises increased thermostability and cellulase activity compared to a wild-type cellobiohydrolase. For example, the disclosure provide polypeptides having increased thermostability and cellulase activity comprising a sequence that is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:2 comprising a C314S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:4 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:12 comprising a C310S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:13 comprising a C312S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:14 comprising a C314S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:15 comprising a C315S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:16 comprising a C313S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:17 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:19 comprising a C313S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:21 comprising a C312S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:22 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:64 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:65 comprising a C407S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:66 comprising a C394S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:67 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:68 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:69 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:70 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:71 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:72 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:73 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:74 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:75 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:76 comprising a C407S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:77 comprising a C394S; or is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:78 comprising a C412S, wherein the foregoing polypeptides have cellulase activity and improved thermostability compared to their corresponding parental (wild-type) protein lacking a Cys→Ser mutation.
The disclosure also provides substantially purified polypeptides that are either recombinantly produced, synthetic made, or otherwise non-naturally generated wherein the polypeptide comprises a sequence as set forth below having from 1-10, 10-20 or 20-30 conservative amino acid substitutions except at the position identified below wherein a C→S substitution is present: SEQ ID NO:2 comprising a C314S; SEQ ID NO:4 comprising a C311S; SEQ ID NO:12 comprising a C310S; SEQ ID NO:13 comprising a C312S; SEQ ID NO:14 comprising a C314S; SEQ ID NO:15 comprising a C315S; SEQ ID NO:16 comprising a C313S; SEQ ID NO:17 comprising a C311S; SEQ ID NO:19 comprising a C313S; SEQ ID NO:21 comprising a C312S; SEQ ID NO:22 comprising a C311S; SEQ ID NO:64 comprising a C400S; SEQ ID NO:65 comprising a C407S; SEQ ID NO:66 comprising a C394S; SEQ ID NO:67 comprising a C400S; SEQ ID NO:68 comprising a C400S; SEQ ID NO:69 comprising a C400S; SEQ ID NO:70 comprising a C400S; SEQ ID NO:71 comprising a C400S; SEQ ID NO:72 comprising a C400S; SEQ ID NO:73 comprising a C400S; SEQ ID NO:74 comprising a C400S; SEQ ID NO:75 comprising a C400S; SEQ ID NO:76 comprising a C407S; SEQ ID NO:77 comprising a C394S; or SEQ ID NO:78 comprising a C412S.
The disclosure provides a recombinant polypeptide comprising a sequence selected from the group consisting of: (a) a polypeptide having at least 85% or greater identity to SEQ ID NO:2, having a Ser at position 314, and wherein the polypeptide has cellulase activity; (b) a polypeptide having at least 70% or greater identity to SEQ ID NO:4, having a Ser at position 311, and wherein the polypeptide has cellulase activity; (c) a polypeptide having 70% or greater identity to a sequence selected from the group consisting of: (i) SEQ ID NO:12 and having a Ser at position 310, (ii) SEQ ID NO:13 and having a Ser at position 312, (iii) SEQ ID NO:14 and having a Ser at position 314, (iv) SEQ ID NO:15 and having a Ser at position 315, (v) SEQ ID NO:16 and having a Ser at position 313, (vi) SEQ ID NO:17 and having a Ser at position 311, (vii) SEQ ID NO:19 and having a Ser at position 313, (viii) SEQ ID NO:21 and having a Ser at position 312, and (ix) SEQ ID NO:22 and having a Ser at position 311, and wherein each of the foregoing polypeptides has cellulase activity; and (d) a chimeric polypeptide comprising at least two domains from two different parental cellobiohydrolase polypeptides, wherein the domains comprise from N- to C-terminus: (segment 1)-(segment 2)-(segment 3)-(segment 4)-(segment 5)-(segment 6)-(segment 7)-(segment 8); wherein: segment 1 comprises a sequence that is at least 50-100% identity to amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 2 comprises a sequence that is at least 50-100% identity to amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 3 comprises a sequence that is at least 50-100% identity to amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 4 comprises a sequence that is at least 50-100% identity to amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 5 comprises a sequence that is at least 50-100% identity to about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 6 comprises a sequence that is at least 50-100% identity to amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 7 comprises a sequence that is at least 50-100% identity to amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”) or SEQ ID NO:4 (“2”); and segment 8 comprises a sequence that is at least 50-100% identity to amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”) or SEQ ID NO:4 (“2”); wherein x1 is residue 43, 44, 45, 46, or 47 of SEQ ID NO:2, or residue 42, 43, 44, 45, or 46 of SEQ ID NO:4 or SEQ ID NO:6; x2 is residue 70, 71, 72, 73, or 74 of SEQ ID NO:2, or residue 68, 69, 70, 71, 72, 73, or 74 of SEQ ID NO:4 or SEQ ID NO:6; x3 is residue 113, 114, 115, 116, 117 or 118 of SEQ ID NO:2, or residue 110, 111, 112, 113, 114, 115, or 116 of SEQ ID NO:4 or SEQ ID NO:6; x4 is residue 153, 154, 155, 156, or 157 of SEQ ID NO:2, or residue 149, 150, 151, 152, 153, 154, 155 or 156 of SEQ ID NO:4 or SEQ ID NO:6; x5 is residue 220, 221, 222, 223, or 224 of SEQ ID NO:2, or residue 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO:4 or SEQ ID NO:6; x6 is residue 256, 257, 258, 259, 260 or 261 of SEQ ID NO:2, or residue 253, 254, 255, 256, 257, 258, 259 or 260 of SEQ ID NO:4 or SEQ ID NO:6; x7 is residue 312, 313, 314, 315 or 316 of SEQ ID NO:2, or residue 309, 310, 311, 312, 313, 314, 315 or 318 of SEQ ID NO:4; and x8 is an amino acid residue corresponding to the C-terminus of the polypeptide have the sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, wherein the chimeric polypeptide comprises a Ser at position 314 of SEQ ID NO:2 or position 311 of SEQ ID NO:4 and wherein the chimeric polypeptide has cellulase activity and improved thermostability and/or pH stability compared to a CBH II polypeptide comprising SEQ ID NO:2, 4, or 6. In one embodiment of the recombinant polypeptide segment 1 comprises amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having 1-10 conservative amino acid substitutions; segment 2 is from about amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 3 is from about amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 4 is from about amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 5 is from about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 6 is from about amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 7 is from about amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; and segment 8 is from about amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions except at position 314 of SEQ ID NO:2, position 311 or SEQ ID NO:4 or 313 of SEQ ID NO:6. In yet another embodiment, the chimeric polypeptide comprises a sequence that is at least 80%, 90%, 95%, 98% or 99% identical to a sequence selected from the group consisting of SEQ ID NO:12-62 and 63.
The disclosure also provides a recombinant polypeptide consisting of a sequence as set forth in SEQ ID NO:12-62 or 63.
The disclosure also provides a polynucleotide encoding any of the polypeptides as described above, vectors containing the polynucleotide and host cells containing the polynucleotide or vector.
The disclosure also provides an enzymatic preparation comprising a polypeptide of the disclosure in substantially purified form or as part of a cell lysate.
The disclosure also provides a method of treating a biomass comprising cellulose, the method comprising contacting the biomass with a polypeptide or enzymatic preparation of the disclosure.



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1A-B SDS-PAGE gel of candidate CBH II parent gene yeast expression culture supernatants. (A) Gel Lanes (Left-to-Right): 1-H. jecorina, 2-Empty vector, 3-H. insolens, 4-C. thermophilum, 5-H. jecorina (duplicate), 6-P. chrysosporium, 7-T. emersonii, 8-Empty vector (duplicate), 9-H. jecorina (triplicate). Numbers at bottom of gel represent concentration of reducing sugar (ug/mL) present in reaction after 2-hr, 50° C. PASC hydrolysis assay. Subsequent SDS-PAGE comparison with BSA standard allowed estimation of H. insolens expression level of 5-10 mg/L. (B) Shows SDS-PAGE gel analysis of S. cerevisiae CBH II expression culture supernatants. CBH II bands appear just below 60 kDa molecular weight standard. Lanes, left-to-right, 1-wild type H. jeco, 2-H. jeco B7P3, 3-H. jeco C311S, 4-wild type C. ther, 5-wild type H. inso, 6-H. inso B7P3, 7-H. inso C314S. Numbers denote μg glucose equivalent/mL reaction volume per mL SDCAA expression culture supernatant equivalent produced during 100-minute incubation with PASC (1 mg/mL) at 50° C. in 50 mM sodium acetate, pH 4.8. Values for lanes 1-4 have been divided by 2 to corret for twice the volume of concentrated culture supernatant being loaded where omitting this correctin would make the specific activity values for the H. insolens enzymes appear artificially low.
FIG. 2A-C shows illustrations of CBH II chimera library block boundaries. (A) H. insolens CBH II catalytic domain ribbon diagram with blocks distinguished by color. CBH II enzyme is complexed with cellobio-derived isofagomine glycosidase inhibitor. (B) Linear representation of H. insolens catalytic domain showing secondary structure elements, disulfide bonds and block divisions denoted by black arrows. (C) Sidechain contact map denoting contacts (side chain heavy atoms within 4.5 Å) that can be broken upon recombination. The majority of broken contacts occur between consecutive blocks.
FIG. 3 shows a number of broken contacts (E) and number of mutations from closest parent (m) for 23 secreted/active and 15 not secreted/not active sample set chimeras.
FIG. 4 shows specific activity, normalized to pH 5.0, as a function of pH for parent CBH II enzymes and three thermostable chimeras. Data presented are averages for two replicates, where error bars for HJPlus and H. jeco denote values for two independent trials. 16-hr reaction, 300 ug enzyme/g PASC, 50° C., 12.5 mM sodium citrate/12.5 mM sodium phosphate buffer at pH as shown.
FIG. 5 shows long-time cellulose hydrolysis assay results (ug glucose reducing sugar equivalent/ug CBH II enzyme) for parents and thermostable chimeras across a range of temperatures. Error bars indicate standard errors for three replicates of HJPlus and H. insolens CBH II enzymes. 40-hr reaction, 100 ug enzyme/g PASC, 50 mM sodium acetate, pH 4.8.
FIG. 6 shows normalized residual activities for validation set chimeras after a 12-h incubation at 63° C. Residual activities for CBH II enzymes in concentrated culture supernatants determined in 2-hr assay with PASC as substrate, 50° C., 25 mM sodium acetate buffer, pH 4.8.
FIG. 7 Map for parent and chimera CBH II enzyme expression vector Yep352/PGK91-1-ss. Vector pictured contains wild type H. jecorina cel6a (CBH II enzyme) gene. For both chimeric and parent CBH II enzymes, the CBD/linker amino acid sequence following the ss Lys-Arg Kex2 site is:







(SEQ ID NO: 8) 







ASCSSVWGQCGGQNWSGPTCCASGSTCVYSNDYYSQCLPGAASSSSSTRA


 


ASTTSRVSPTTSRSSSATPPPGSTTTRVPPVGSGTATYS.






FIG. 8 shows Observed and predicted T50 values for CBH II parents and 51 CBH II chimeras. Line denotes linear regression model equation (parameters in Table 7). Parent CBH II T50 values are denoted as squares.
FIG. 9A-C shows CBH II specific activities toward Avicel as a function of temperature. (a) CBH II parent and chimera specific activities. (b) CBH II parent, C311S mutant and B7P3 single block substitution chimera specific activities. Reactions were run for 16 hours in 50 mM sodium acetate, pH 4.8 with an Avicel concentration of 15 mg/mL. (c) CBH II parent, single point mutant and single block substitution chimera activities (μg/glucose/mL reaction) toward avicel as a function of temperature. Reactions were run for 150 minutes in 50 mM sodium acetate, pH 4.8 with an avicel concentration of 15 mg/mL. CBH II yeast culture supernatants were dosed to achieve roughly equivalent reducing sugar product concentrations at 55° C. Data presented are averages of two independent replicates with error bars indicating the duplicate activity values for each temperature point.
FIG. 10 shows ClustalW multiple sequence alignment for block 7 from parent 1, H. insolens and parent 3, C. thermophilum. Arrows denote residues changed in reversion mutants.
FIG. 11 shows T50 values for 21111331 chimera point mutants. Values shown as average of two independent duplicates, error bars indicate duplicate T50 values for each point mutant. Inactivation was carried out for 10 minutes at the temperature being tested in 50 mM sodium acetate buffer, pH 4.8. Residual activity was determined by incubation with 1 g/L phosphoric acid swollen cellulose (PASC) in above buffer for 100 minutes at 50° C.
FIG. 12 shows T50 values for H. insolens and H. jecorina parent CBH IIs, Ser single point mutants and B7P3 block substitution chimeras. Values shown as average of three independent replicates, error bars indicate one standard deviation for each CBH II. Inactivation was carried out for 10 minutes at the temperature being tested in 50 mM sodium acetate buffer, pH 4.8. Residual activity was determined by incubation with 1 g/L phosphoric acid swollen cellulose (PASC) in above buffer for 100 minutes at 50° C.
FIG. 13 shows T50 values for CBH II chimeras 31311112, 13231111 and the wild type CBH II catalytic domain from P. chrysosporium (fused to the H. jecorina CBM) and heterologously secreted from S. cerevisiae. Values shown as two independent replicates with error bars indicating values for each trial. Inactivation was carried out for 10 minutes at the temperature tested, in 50 mM sodium acetate buffer, pH 4.8. Residual activity was determined by incubation with 1 g/L phosphoric acid swollen cellulose (PASC) in above buffer for 100 minutes at 50° C.
FIG. 14A-D shows CBH II recombination block interfaces. (a) Inter-block sites where novel non-parental residue pairs are possible (connected spheres) are usually surface-exposed, potentially allowing solvent to screen the interactions. (b) An example interface (B5-B6) illustrates conservation of the backbone (cartoons for aligned H. jecorina and H. insolens), variable residues on the surface, and the comparatively rare possibility of a novel buried hydrophobic pair at residues 173 and 253 (arrow). (c) Blocks 1-4 from H. jecorina (black cartoon) match cognate H. insolens blocks (color-coded cartoon) without large deviations, though movement associated with substrate binding is observed (arrow) in part of B3 (yellow). (d) Cognate blocks 5-8 are also similar, though the indel at the B6,B7 junction (arrow) will require conformational change.
FIG. 15 shows a structural analysis of C314S mutation and its stabilizing effect. (a) Hydrogen positions for high-resolution H. insolens structure (1ocn) were added with REDUCE.1 (b) The reconfigured geometry of the analogous serine structure was modeled in PyMOL (http:(//)www.pymol.org). Sidechain optimization in the SHARPEN2 modeling platform (with an all-atom Rosetta energy function) also suggested that both the Cys314 and Ser314 would donate hydrogen bonds to the carbonyl of Pro339, and accept hydrogen bonds from the amide of Gly316. The superior hydrogen bonding capacity of serine may play a role in the greater stability of the serine containing variants. Another possible explanation is geometric complementarity. Specifically, the Cys position from 1ocn shows evidence of conformational strain in that the sidechain is noticeably bent (i.e. the improper dihedral angle from N—C—Cα-Cβ is 6° from the standard position), increasing the distance from the Pro carbonyl. Numbers in figure not preceded by letters denote hydrogen bond distances (Å).



DETAILED DESCRIPTION
As used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a domain” includes a plurality of such domains and reference to “the protein” includes reference to one or more proteins, and so forth.
Also, the use of “or” means “and/or” unless stated otherwise. Similarly, “comprise,” “comprises,” “comprising” “include,” “includes,” and “including” are interchangeable and not intended to be limiting.
It is to be further understood that where descriptions of various embodiments use the term “comprising,” those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language “consisting essentially of” or “consisting of.”
Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Thus, as used throughout the instant application, the following terms shall have the following meanings.
Recent studies have documented the superior performance of cellulases from thermophilic fungi relative to their mesophilic counterparts in laboratory scale biomass conversion processes, where enhanced stability leads to retention of activity over longer periods of time at both moderate and elevated temperatures. Fungal cellulases are attractive because they are highly active and can be expressed in fungal hosts such as Hypocrea jecorina (anamorph Trichoderma reesei) at levels up to 40 g/L in the supernatant. Unfortunately, the set of documented thermostable fungal cellulases is small. In the case of the processive cellobiohydrolase class II (CBH II) enzymes, fewer than 10 natural thermostable gene sequences are annotated in the CAZy database.
As described more fully herein, using recursive chimeric polypeptide generation and analysis particular stabilizing domains and ultimately specific amino acid were identified the imparted thermostability and improved activity.
As will be described in more detail below, the invention is based, at least in part, on the generation and expression of novel enzymes that catalyze the hydrolysis of cellulose. In one embodiment, novel polypeptides that have been engineered to hydrolyze cellose at increased temperatures are provided. Such polypeptides include cellobiohydrolase variants that have been altered to include amino acid substitutions at specified residues. While these variants will be described in more detail below, it is understood that polypeptides of the disclosure may contain one or more modified amino acids. The presence of modified amino acids may be advantageous in, for example, (a) increasing a polypeptide's half-life, (b) thermostability, and (c) increased substrate turnover. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N—X—S/T motifs during expression in mammalian cells) or modified by synthetic means. Accordingly, a “mutant”, “variant” or “modified” protein, enzyme, polynucleotide, gene, or cell, means a protein, enzyme, polynucleotide, gene, or cell, that has been altered or derived, or is in some way different or changed, from a parent protein, enzyme, polynucleotide, gene, or cell. A mutant or modified protein or enzyme is usually, although not necessarily, expressed from a mutant polynucleotide or gene.
A “mutation” means any process or mechanism resulting in a mutant protein, enzyme, polynucleotide, gene, or cell. This includes any mutation in which a protein, enzyme, polynucleotide, or gene sequence is altered, and any detectable change in a cell arising from such a mutation. Typically, a mutation occurs in a polynucleotide or gene sequence, by point mutations, deletions, or insertions of single or multiple nucleotide residues. A mutation includes polynucleotide alterations arising within a protein-encoding region of a gene as well as alterations in regions outside of a protein-encoding sequence, such as, but not limited to, regulatory or promoter sequences. A mutation in a gene can be “silent”, i.e., not reflected in an amino acid alteration upon expression, leading to a “sequence-conservative” variant of the gene. This generally arises when one amino acid corresponds to more than one codon.
Non-limiting examples of a modified amino acid include a glycosylated amino acid, a sulfated amino acid, a prenlyated (e.g., farnesylated, geranylgeranylated) amino acid, an acetylated amino acid, an acylated amino acid, a pegylated amino acid, a biotinylated amino acid, a carboxylated amino acid, a phosphorylated amino acid, and the like. References adequate to guide one of skill in the modification of amino acids are replete throughout the literature. Example protocols are found in Walker (1998) Protein Protocols on CD-ROM (Humana Press, Towata, N.J.).
Recombinant methods for producing and isolating modified cellobiohydrolase polypeptides of the disclosure are described herein. In addition to recombinant production, the polypeptides may be produced by direct peptide synthesis using solid-phase techniques (e.g., Stewart et al. (1969) Solid-Phase Peptide Synthesis (WH Freeman Co, San Francisco); and Merrifield (1963) J. Am. Chem. Soc. 85: 2149-2154). Peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer.
“Cellobiohydrolase II” or “CBH II enzyme” means an enzyme in the cellulase family 6 proteins, which are widely distributed in bacteria and fungi. The enzymes are involved in hydrolysis of cellulose.
By “cellulase activity” means an enzyme that is capable of hydrolyzing cellulose. Cellulase refers to a class of enzymes produced by fungi, bacteria, and protozoans that catalyze the hydrolysis of cellulose. However, there are also cellulases produced by other types of organisms such as plants and animals. The EC number for this group of enzymes is EC 3.2.1.4. There are five generatl types of cellulases based on the type of reaction catalyzed: endo-cellulase; exo-cellulase, within this category there are two main types of exo-cellulases (or cellobiohydrolases, abbreviate CBH)—one type working processively from the reducing end, and one type working processively from the non-reducing end of cellulose; cellobiase or beta-glucosidase hydrolyses; oxidative cellulases; and cellulose phosphorylases that depolymerize cellulose using phosphates instead of water. Most fungal cellulases have two-domains: a catalytic domain and a cellulose binding domain, that are connected by a flexible linker. In specific embodiments of the disclosure the cellulase activity is a CBH activity. The sequences described herein include, in some instances, both the cellulose binding domain and the catalytic domain or just the catalytic domain. In such instances where only the catalytic domain sequence is provided it will be recognized that a cellulose binding domain (CBD) such as that provided in SEQ ID NO:8, may be functional linked (either as part of the coding sequence or fused later) to the catalytic domain either directly or through a linker.
A “protein” or “polypeptide”, which terms are used interchangeably herein, comprises one or more chains of chemical building blocks called amino acids that are linked together by chemical bonds called peptide bonds. An “enzyme” means any substance, preferably composed wholly or largely of protein, that catalyzes or promotes, more or less specifically, one or more chemical or biochemical reactions. A “native” or “wild-type” protein, enzyme, polynucleotide, gene, or cell, means a protein, enzyme, polynucleotide, gene, or cell that occurs in nature.
An “amino acid sequence” is a polymer of amino acids (a protein, polypeptide, etc.) or a character string representing an amino acid polymer, depending on context. The terms “protein,” “polypeptide,” and “peptide” are used interchangeably herein. “Amino acid” is a molecule having the structure wherein a central carbon atom is linked to a hydrogen atom, a carboxylic acid group (the carbon atom of which is referred to herein as a “carboxyl carbon atom”), an amino group (the nitrogen atom of which is referred to herein as an “amino nitrogen atom”), and a side chain group, R. When incorporated into a peptide, polypeptide, or protein, an amino acid loses one or more atoms of its amino acid carboxylic groups in the dehydration reaction that links one amino acid to another. As a result, when incorporated into a protein, an amino acid is referred to as an “amino acid residue.”
A particular amino acid sequence of a given protein (i.e., the polypeptide's “primary structure,” when written from the amino-terminus to carboxy-terminus) is determined by the nucleotide sequence of the coding portion of a mRNA, which is in turn specified by genetic information, typically genomic DNA (including organelle DNA, e.g., mitochondrial or chloroplast DNA). Thus, determining the sequence of a gene assists in predicting the primary sequence of a corresponding polypeptide and more particular the role or activity of the polypeptide or proteins encoded by that gene or polynucleotide sequence.
“Conservative amino acid substitution” or, simply, “conservative variations” of a particular sequence refers to the replacement of one amino acid, or series of amino acids, with essentially identical amino acid sequences. One of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a percentage of amino acids in an encoded sequence result in “conservative variations” where the alterations result in the deletion of an amino acid, addition of an amino acid, or substitution of an amino acid with a chemically similar amino acid.
Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, one conservative substitution group includes Alanine (A), Serine (S), and Threonine (T). Another conservative substitution group includes Aspartic acid (D) and Glutamic acid (E). Another conservative substitution group includes Asparagine (N) and Glutamine (Q). Yet another conservative substitution group includes Arginine (R) and Lysine (K). Another conservative substitution group includes Isoleucine, (I) Leucine (L), Methionine (M), and Valine (V). Another conservative substitution group includes Phenylalanine (F), Tyrosine (Y), and Tryptophan (W).
Thus, “conservative amino acid substitutions” of a listed polypeptide sequence (e.g., SEQ ID NOs: 2, 4, 6, and 12-78) include substitutions of a percentage, typically less than 10%, of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group. Accordingly, a conservatively substituted variation of a polypeptide of the disclosure can contain 100, 75, 50, 25, or 10 substitutions with a conservatively substituted variation of the same conservative substitution group.
It is understood that the addition of sequences which do not alter the encoded activity of a nucleic acid molecule, such as the addition of a non-functional or non-coding sequence, is a conservative variation of the basic nucleic acid. The “activity” of an enzyme is a measure of its ability to catalyze a reaction, i.e., to “function”, and may be expressed as the rate at which the product of the reaction is produced. For example, enzyme activity can be represented as the amount of product produced per unit of time or per unit of enzyme (e.g., concentration or weight), or in terms of affinity or dissociation constants. As used interchangeably herein a “cellobiohydrolase activity or cellulase activity”, “biological activity of cellobiohydrolase or cellulase” or “functional activity of cellobiohydrolase or cellulase”, refers to an activity exerted by a protein, polypeptide having cellulase activity and in specific embodiments cellobiohydrolase activity on a cellulose substrate, as determined in vivo, or in vitro, according to standard techniques.
One of skill in the art will appreciate that many conservative variations of the nucleic acid constructs which are disclosed yield a functionally identical construct. For example, as discussed above, owing to the degeneracy of the genetic code, “silent substitutions” (i.e., substitutions in a nucleic acid sequence which do not result in an alteration in an encoded polypeptide) are an implied feature of every nucleic acid sequence which encodes an amino acid. Similarly, “conservative amino acid substitutions,” in one or a few amino acids in an amino acid sequence are substituted with different amino acids with highly similar properties, are also readily identified as being highly similar to a disclosed construct. Such conservative variations of each disclosed sequence are a feature of the polypeptides provided herein.
“Conservative variants” are proteins or enzymes in which a given amino acid residue has been changed without altering overall conformation and function of the protein or enzyme, including, but not limited to, replacement of an amino acid with one having similar properties, including polar or non-polar character, size, shape and charge. Amino acids other than those indicated as conserved may differ in a protein or enzyme so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and can be, for example, at least 30%, at least 50%, at least 70%, at least 80%, or at least 90%, as determined according to an alignment scheme. As referred to herein, “sequence similarity” means the extent to which nucleotide or protein sequences are related. The extent of similarity between two sequences can be based on percent sequence identity and/or conservation. “Sequence identity” herein means the extent to which two nucleotide or amino acid sequences are invariant. “Sequence alignment” means the process of lining up two or more sequences to achieve maximal levels of identity (and, in the case of amino acid sequences, conservation) for the purpose of assessing the degree of similarity. Numerous methods for aligning sequences and assessing similarity/identity are known in the art such as, for example, the Cluster Method, wherein similarity is based on the MEGALIGN algorithm, as well as BLASTN, BLASTP, and FASTA (Lipman and Pearson, 1985; Pearson and Lipman, 1988). When using all of these programs, the preferred settings are those that results in the highest sequence similarity.
Non-conservative modifications of a particular polypeptide are those which substitute any amino acid not characterized as a conservative substitution. For example, any substitution which crosses the bounds of the six groups set forth above. These include substitutions of basic or acidic amino acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for Val, Ile, Leu or Met), aromatic amino acid for basic or acidic amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or any other substitution not replacing an amino acid with a like amino acid. Basic side chains include lysine (K), arginine (R), histidine (H); acidic side chains include aspartic acid (D), glutamic acid (E); uncharged polar side chains include glycine (G), asparagine (N), glutamine (Q), serine (S), threonine (T), tyrosine (Y), cysteine (C); nonpolar side chains include alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), methionine (M), tryptophan (W); beta-branched side chains include threonine (T), valine (V), isoleucine (I); aromatic side chains include tyrosine (Y), phenylalanine (F), tryptophan (W), histidine (H).
A “parent” protein, enzyme, polynucleotide, gene, or cell, is any protein, enzyme, polynucleotide, gene, or cell, from which any other protein, enzyme, polynucleotide, gene, or cell, is derived or made, using any methods, tools or techniques, and whether or not the parent is itself native or mutant. A parent polynucleotide or gene encodes for a parent protein or enzyme.
In addition to providing variants of CBH II polypeptides, chimeric polypeptides that comprise: 1) a variant domain isolated from a first parental strand and modified to include an amino acid substitution; and 2) a domain isolated from a second parental strand either unmodified or modified to include a new activity or an activity that a complements the domain, are provided. Methods for engineering a chimeric polypeptide of the disclosure are disclosed herein.
The disclosure provides cellulase and cellobiohydrolase (CBH) II variants, mutants and chimeras having increased thermostability compared to a wild-type or parental protein, wherein the wild-type protein consisting of SEQ ID NO:2, 4 or 6. The variant comprises a Serine in the C-terminal region in a motif comprising the sequence GEXDG, wherein X is C, A or G (SEQ ID NO:107), wherein X is substituted with Serine, the variant comprising cellulase activity and wherein the polypeptide has increased thermostability compared to a wild-type cellulase lacking a serine in the sequence GEXDG (SEQ ID NO:107). In one embodiment, the variants comprise at least a mutation of a Cys→Ser in the motif GECDG (see, e.g., SEQ ID NO:2 from amino acid 312-316) found in most cellulase and cellobiohydrolase II proteins (as described more fully below) and may comprise additional mutations that improve thermostability or activity. The identity between cellulases can be quite low. The serine substitution as described above is applicable to any cellulase having the motif of SEQ ID NO:107 (e.g., wherein the polypeptide has at least 60% or greater identity to SEQ ID NO:2 or 4).
For example, the disclosure provide polypeptides having increased thermostability and cellulase activity comprising a sequence that is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:2 comprising a C314S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:4 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:12 comprising a C310S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:13 comprising a C312S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:14 comprising a C314S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:15 comprising a C315S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:16 comprising a C313S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:17 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:19 comprising a C313S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:21 comprising a C312S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:22 comprising a C311S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:64 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:65 comprising a C407S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:66 comprising a C394S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:67 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:68 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:69 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:70 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:71 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:72 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:73 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:74 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:75 comprising a C400S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:76 comprising a C407S; is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:77 comprising a C394S; or is at least 85%, 90%, 95%, 98%, 99% identical SEQ ID NO:78 comprising a C412S, wherein the foregoing polypeptides have cellulase activity and improved thermostability compared to their corresponding parental (wild-type) protein lacking a Cys→Ser mutation.
In yet another embodiment, the disclosure provides polypeptide as described above, however, they further comprise at least one addition mutation that can be determined by alignment to SEQ ID NO:64, wherein SEQ ID NO:64 comprises a Pro at position 413, or a Ser or Thr at position 231, or a Ser or Thr at position 305, or a Gln or Asn at position 410, or a Glu at position 82, or any combination of the foregoing. Similar substitutions can be identified by sequence alignment of the amino acid sequence of SEQ ID NO:64 with those of SEQ ID NOs:2, 4, 6, 12-63, and 65-78.
The disclosure also provides substantially purified polypeptides that are either recombinantly produced, synthetic made, or otherwise non-naturally generated wherein the polypeptide comprise a sequence as set forth below having from 1-10, 10-20 or 20-30 conservative amino acid substitutions except at the position identified below wherein a C→S substitution is present:
SEQ ID NO:2 comprising a C314S;
SEQ ID NO:4 comprising a C311S;
SEQ ID NO:12 comprising a C310S;
SEQ ID NO:13 comprising a C312S;
SEQ ID NO:14 comprising a C314S;
SEQ ID NO:15 comprising a C315S;
SEQ ID NO:16 comprising a C313S;
SEQ ID NO:17 comprising a C311S;
SEQ ID NO:19 comprising a C313S;
SEQ ID NO:21 comprising a C312S;
SEQ ID NO:22 comprising a C311S;
SEQ ID NO:64 comprising a C400S;
SEQ ID NO:65 comprising a C407S;
SEQ ID NO:66 comprising a C394S;
SEQ ID NO:67 comprising a C400S;
SEQ ID NO:68 comprising a C400S;
SEQ ID NO:69 comprising a C400S;
SEQ ID NO:70 comprising a C400S;
SEQ ID NO:71 comprising a C400S;
SEQ ID NO:72 comprising a C400S;
SEQ ID NO:73 comprising a C400S;
SEQ ID NO:74 comprising a C400S;
SEQ ID NO:75 comprising a C400S;
SEQ ID NO:76 comprising a C407S;
SEQ ID NO:77 comprising a C394S; or
SEQ ID NO:78 comprising a C412S.
“Isolated polypeptide” refers to a polypeptide which is separated from other contaminants that naturally accompany it, e.g., protein, lipids, and polynucleotides. The term embraces polypeptides which have been removed or purified from their naturally-occurring environment or expression system (e.g., host cell or in vitro synthesis).
“Substantially pure polypeptide” refers to a composition in which the polypeptide species is the predominant species present (i.e., on a molar or weight basis it is more abundant than any other individual macromolecular species in the composition), and is generally a substantially purified composition when the object species comprises at least about 50 percent of the macromolecular species present by mole or % weight. Generally, a substantially pure polypeptide composition will comprise about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, and about 98% or more of all macromolecular species by mole or % weight present in the composition. In some embodiments, the object species is purified to essential homogeneity (i.e., contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species. Solvent species, small molecules (<500 Daltons), and elemental ion species are not considered macromolecular species.
“Reference sequence” refers to a defined sequence used as a basis for a sequence comparison. A reference sequence may be a subset of a larger sequence, for example, a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence can be at least 20 nucleotide or amino acid residues in length, at least 25 nucleotide or residues in length, at least 50 nucleotides or residues in length, or the full length of the nucleic acid or polypeptide. Since two polynucleotides or polypeptides may each (1) comprise a sequence (i.e., a portion of the complete sequence) that is similar between the two sequences, and (2) may further comprise a sequence that is divergent between the two sequences, sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two polynucleotides or polypeptides over a “comparison window” to identify and compare local regions of sequence similarity.
“Sequence identity” means that two amino acid sequences are substantially identical (i.e., on an amino acid-by-amino acid basis) over a window of comparison. The term “sequence similarity” refers to similar amino acids that share the same biophysical characteristics. The term “percentage of sequence identity” or “percentage of sequence similarity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical residues (or similar residues) occur in both polypeptide sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity (or percentage of sequence similarity). With regard to polynucleotide sequences, the terms sequence identity and sequence similarity have comparable meaning as described for protein sequences, with the term “percentage of sequence identity” indicating that two polynucleotide sequences are identical (on a nucleotide-by-nucleotide basis) over a window of comparison. As such, a percentage of polynucleotide sequence identity (or percentage of polynucleotide sequence similarity, e.g., for silent substitutions or other substitutions, based upon the analysis algorithm) also can be calculated. Maximum correspondence can be determined by using one of the sequence algorithms described herein (or other algorithms available to those of ordinary skill in the art) or by visual inspection.
As applied to polypeptides, the term substantial identity or substantial similarity means that two peptide sequences, when optimally aligned, such as by the programs BLAST, GAP or BESTFIT using default gap weights or by visual inspection, share sequence identity or sequence similarity. Similarly, as applied in the context of two nucleic acids, the term substantial identity or substantial similarity means that the two nucleic acid sequences, when optimally aligned, such as by the programs BLAST, GAP or BESTFIT using default gap weights (described elsewhere herein) or by visual inspection, share sequence identity or sequence similarity.
One example of an algorithm that is suitable for determining percent sequence identity or sequence similarity is the FASTA algorithm, which is described in Pearson, W. R. & Lipman, D. J., (1988) Proc. Natl. Acad. Sci. USA 85:2444. See also, W. R. Pearson, (1996) Methods Enzymology 266:227-258. Preferred parameters used in a FASTA alignment of DNA sequences to calculate percent identity or percent similarity are optimized, BL50 Matrix 15: −5, k-tuple=2; joining penalty=40, optimization=28; gap penalty −12, gap length penalty=−2; and width=16.
Another example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity or percent sequence similarity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151-153, 1989. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity (or percent sequence similarity) relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux et al., (1984) Nuc. Acids Res. 12:387-395).
Another example of an algorithm that is suitable for multiple DNA and amino acid sequence alignments is the CLUSTALW program (Thompson, J. D. et al., (1994) Nuc. Acids Res. 22:4673-4680). CLUSTALW performs multiple pairwise comparisons between groups of sequences and assembles them into a multiple alignment based on sequence identity. Gap open and Gap extension penalties were 10 and 0.05 respectively. For amino acid alignments, the BLOSUM algorithm can be used as a protein weight matrix (Henikoff and Henikoff, (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919).
As mentioned above, cellobiohydrolase and cellulase family members can be identified by sequence alignment and a substitution in the motif GECDG (see, e.g., SEQ ID NO:2 from amino acid 312-316) made. The modified polypeptide may then be assayed for activity as described below at various temperatures and conditions to identify those modifications that introduce a favorable activity. Exemplary sequences can be found in the following GenBank accession numbers, the sequences of which are incorporated herein by reference.
















P07987
Q6E581



GUX2_TRIRE
Q6E581_9AGAR



Q9HEY8
B7X9Z0



Q9HEY8_TRIRE
B7X9Z0_COPC1



Q7LSP2
A8NEJ3



Q7LSP2_TRIKO
A8NEJ3_COPC7



Q6UJX9
Q96V98



Q6UJX9_TRIVI
Q96V98_ORPSP



A3QVU7
Q7Z7X6



A3QVU7_TRIVI
Q7Z7X5_PIREQ



1HCL5
Q870B2



Q1HCL5_TRIKO
Q87082_9FUNG



Q66PN1
Q874E1



Q66PN1_9HYPO
Q874E1_ORPSP



B5TWC7
A9FHT2



B5TWC7_9HYPO
A9FHT2_SORC5



Q9C1S9
B0FEV9



GUX6_HUMIN
B0FEV9_9FUNG



Q2GMP2
Q6EY63



Q2GMP2_CHAGB
Q6EY63_9FUNG



A7E6G7
Q6EH22



A7E6G7_SCLS1
Q6EH22_NEOFR



Q0UPA5
B6EA50



Q0UPA5_PHANO
B6EAS0_NEOPA



A6S7A6
B0FEV4



A6S7A6_BOTFB
B0FEV4_NEOPA



P49075
6EIY8



GUX3_AGABI
Q6EIY8_NEOFR



Q02321
Q9UW10



Q02321_PHACH
Q9UW10_9FUNG



Q9C1R4
Q12646



Q9C1R4_LENED
Q12646_NEOPA



Q96VU2
Q6A4K7



Q96VU2_LENED
Q6A4K7_9FUNG



B2ABX7
Q9UW11



B2ABX7_PODAN
Q9UW11_9FUNG



A4RPH6
Q9P8Q8



A4RPH6_MAGGR
Q9P8Q8_9FUNG




B0FEV8




B0FEV8_9FUNG










In yet other embodiments, the family of variant cellulase polypeptide having improved thermostability include those set forth in the following table having a C→S, G→S or A→S substitution. In addition, polypeptides having 85%, 90%, 95%, 98%, or 99% sequence identity to any of the following sequences having the identified substitutions in the following table, having cellulase activity and thermostability are also encompassed by the disclosure.
Alignment of amino acid frame bracketing H. jecorina CBH II Cys311 for protein sequences having highest identity to H. jecorina CBH II. Residues at 311 equivalent position denoted by bold, underline are shown. Sequences for recombinant H. insolens and P. chrys CBH IIs studied in this work are denoted as H. inso and P. chrys. Fifty-four of the 250 most identical sequences were excluded due to redundancy (i.e. point mutants for structural studies or >95% identical isoforms). The accession number for the cellulase is identified and the corresponding sequence is incorporated herein by reference as if copied directly from the accession number. The sequences associated with the accession numbers are referred to as SEQ ID NO:79-106. A replacement of the bold-underlined residue (e.g., C, A or G) with S. The number in parenthesis following the sequence identified the SEQ ID NO:)










H.jeco
----T---G---D----S---L--LDSFVWVKPGGECDG--T----S-------------
  (4)



 


XP_001903170
----T---G---L----D---I--EDAFVWIKPGGECDG--T----S-------------
 (79)


 


XP_001226029
----T---G---H----D---L--LDAFVWIKPGGECDG--T----S-------------
 (80)


 


XP_360146
----T---G---S----E---L--ADAFVWIKPGGECDG--V----S-------------
 (81)


 


H.inso
----T---G---H----Q---Y--VDAFVWVKPGGECDG--T----S-------------
  (2)


 


XP_001598803
----T---G---D----A---L--EDAFVWVKPGGEADG--T----S-------------
 (82)


 


XP_001796781
----T---D---D----P---L--LDAYVWVKPGGEGDG--T----S-------------
 (83)


 


AAA50608
----T---G---S----S---L--IDAIVWVKPGGECDG--T----S-------------
 (84)


 


AAK28357
----T---G---S----S---L--IDSIVWVKPGGECDG--T----S-------------
 (85)


 


BAH59082
----T---G---S----P---L--IDSIVWVKPGGECDG--T----S-------------
 (86)


 


AAT64008
----T---G---S----S---L--IDAIVWIKPGGECDG--T----T-------------
 (87)


 


P.crys
----T---G---S----Q---F--IDSIVWVKPGGECDG--T----S-------------
 (12)


 


BAH59083
----T---P---S----S---L--IDSIVWVKPGGEADG--T----S-------------
 (88)


 


XP_001833045
----T---P---S----S---A--IDAIVWIKPGGEADG--T----S-------------
 (89)


 


XP_002391276
----T---G---S----S---L--IDSIVWVKPGGE------------------------
 (90)


 


AAD51055
----P---D---S----SKP-L--LDAYMWIKTPGEADG--S----S-------------
 (91)


 


ABY52798
----S---G---Y----PL-----LDAFMWLKTPGEADG--S----A-------------
 (92)


 


AAF34679
----P---D---A----SMP-L--LDAYMWLKTPGEADG--S----A-------------
 (93)


 


ABY52797
----P---S---K----P---L--LDAYMWIKTPGEADG--S----S-------------
 (94)


 


AAR08200
----PNP-G---M----P---L--LDAYMWLKTPGEADG--S----S-------------
 (95)


 


AAB92678
----P---N---P----GSMPL--LDAYMWIKTPGEADG--S----S-------------
 (96)


 


ABY52799
----S---P---DPEKFP---L--LDAYFWLKPPGEADG--S----D-------------
 (97)


 


AAC60491
----T---G---D----A---N--IDAYLWVKPPGEADG---------------------
 (98)


 


AAC09068
----V---K---M----P---L--LDAYMWLKTPGEADG--S----D-------------
 (99)


 


ZP_04371095
----T---G---D----A---A--VDAFLWIKPPGEADG--C----A-------------
(100)


 


ZP_03818362
----T---G---D----S---Q--IDAFLWVKIVGEADG---------------------
(101)


 


ZP_03817628
----T---G---D----P---Q--IDAFLWVKIPGEADG---------------------
(102)


 


ZP_04331392
----T---G---N----P---L--IDAFIWTKLPGEADG---------------------
(103)


 


2BOE-X
----T---G---D----P---M--IDAFLWIKLPGEADG---------------------
(104)


 


ZP_04608509
----T---G---D----S---A--IAAYLWVKLPGEADG---------------------
(105)


 


P26414
----T---G---D----P---A--IDAFLWIKPPGEADG---------------------
(106)






For the purposes of the disclosure, a polypeptide of the disclosure exhibits improved thermostability with respect to a corresponding parent polypeptide if it has a T50 which is at least about 4° C., or at least about 9° C. higher than that of the parent cellulase, or for example a cellobiohydrolase having a T50 from about 4° C. to about 30° C. higher, or any amount therebetween, or a T50 from about 9° C. to about 30° C. higher, or any amount therebetween, when compared to that of the parent cellobiohydrolase. The T50 is the temperature at which the modified or the natural enzyme retains 50% of its residual activity after a pre-incubation for 15 minutes and is determined by the assay detailed in Examples below or as known in the art.
The modified cellobiohydrolases or cellulases of the disclosure may have T50 which is about 4° C. to about 30° C. higher than that of a corresponding parent cellobiohydrolase (e.g., SEQ ID NO:2, 4 or 6), or any range therebetween, about 5° C. to about 20° C. higher, or any range therebetween, about 8° C. to about 15° C. higher, or any range therebetween, or from about 9° C. to about 15° C. higher, or any range therebetween. For example, the modified cellulase may have a T50 that is at least about 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30° C. higher than that of the corresponding parent cellobiohydrolase.
The variants identified herein can also be used to generate chimeric cellobiohydrolases. For example, SCHEMA has been used previously to create families of hundreds of active β-lactamase and cytochrome P450 enzyme chimeras. SCHEMA uses protein structure data to define boundaries of contiguous amino acid “blocks” which minimize <E>, the library average number of amino acid sidechain contacts that are broken when the blocks are swapped among different parents. It has been shown that the probability that a β-lactamase chimera was folded and active was inversely related to the value of E for that sequence. The RASPP (Recombination as Shortest Path Problem) algorithm was used to identify the block boundaries that minimized <E> relative to the library average number of mutations, <m>. More than 20% of the  ̃500 unique chimeras characterized from a β-lactamase collection comprised of 8 blocks from 3 parents (38=6,561 possible sequences) were catalytically active. A similar approach produced a 3-parent, 8-block cytochrome P450 chimera family containing more than 2,300 novel, catalytically active enzymes. Chimeras from these two collections were characterized by high numbers of mutations, 66 and 72 amino acids on average from the closest parent, respectively. SCHEMA/RASPP thus enabled design of chimera families having significant sequence diversity and an appreciable fraction of functional members.
It has also been shown that the thermostabilities of SCHEMA chimeras can be predicted based on sequence-stability data from a small sample of the sequences. Linear regression modeling of thermal inactivation data for 184 cytochrome P450 chimeras showed that SCHEMA blocks made additive contributions to thermostability. More than 300 chimeras were predicted to be thermostable by this model, and all 44 that were tested were more stable than the most stable parent. It was estimated that as few as 35 thermostability measurements could be used to predict the most thermostable chimeras. Furthermore, the thermostable P450 chimeras displayed unique activity and specificity profiles, demonstrating that chimeragenesis can lead to additional useful enzyme properties. Here SCHEMA recombination of CBH II enzymes can generate chimeric cellulases that are active on phosphoric acid swollen cellulose (PASC) at high temperatures, over extended periods of time, and broad ranges of pH.
Using the methods described herein a number of chimeric polypeptides having cellobiohydrolases activity were generated having improved characteristics compared to the wild-type parental CBH II proteins.
A diverse family of novel CBH II enzymes was constructed by swapping blocks of sequence from three fungal CBH II enzymes. Twenty-three of 48 chimeric sequences sampled from this set were secreted in active form by S. cerevisiae, and five have half-lives at 63° C. that were greater than the most stable parent. Given that this 48-member sample set represents less than 1% of the total possible 6,561 sequences, we predict that this one collection of chimeras already contains hundreds of active, thermostable CBH II enzymes, a number that dwarfs the approximately twenty fungal CBH II enzymes in the CAZy database.
The approach of using the sample set sequence-stability data to identify blocks that contribute positively to chimera thermostability was validated by finding that all 10 catalytically active chimeras in the second CBH II validation set were more thermostable than the most stable parent, a naturally-thermostable CBH II from the thermophilic fungus, H. insolens. This disclosure has thus far generated a total of 33 new CBH II enzymes that are expressed in catalytically active form in S. cerevisiae, 15 of which are more thermostable than the most stable parent from which they were constructed. These 15 thermostable enzymes are diverse in sequence, differing from each other and their closest natural homologs at as many as 94 and 58 amino acid positions, respectively.
Analysis of the thermostabilities of CBH II chimeras in the combined sample and validation sets indicates that the four thermostabilizing blocks identified, B1P1, B6P3, B7P3 and B8P2, make cumulative contributions to thermal stability when present in the same chimera. Four of the five sample set chimeras that are more thermostable than the H. insolens CBH II contain either two or three of these stabilizing blocks (Table 1). The ten active members of the validation set, all of which are more stable than the H. insolens enzyme, contain at least two stabilizing blocks, with five of the six most thermostable chimeras in this group containing either three or four stabilizing blocks.
The disclosure demonstrates that stabilizing blocks can be recombined to create novel highly stable, active cellulases. The stability regression model predicts that the CBH II SCHEMA library contains 2,026 chimeras that are more stable than the most stable parent enzyme. These chimeras are diverse and distinct from the native cellulases: they differ from the parents by between 8 and 72 mutations (an average of 50) and from each other by an average of 63 mutations. A total of 33 genes from this set were synthesized and expressed in S. cerevisiae: every one of these chimeric CBH IIs was found to be more stable than the most stable parent cellulase, from the thermophilic fungus H. insolens, as measured either by its half-life of inactivation at 63° C. or T50. Reducing the sequence complexity by making chimeras of only eight blocks allowed the generation of a sequence-stability model and identification of a single highly stabilizing sequence block. By testing only ten amino acid substitutions in this block a single, highly stabilizing substitution was identified. The very large stabilizing effect of the C313S (with reference to SEQ ID NO:6; C314S, SEQ ID NO:2 and C311S, SEQ ID NO:4) substitution observed across the chimeras and in the native P. chrysosporium, H. insolens and H. jecorina CBH II enzymes suggests that mutation of any residue at this position to Ser may stabilize any family 6 cellulase into which it is introduced.
Minimizing the number of broken contacts upon recombination (FIG. 2C) allows the blocks to be approximated as decoupled units that make independent contributions to the stability of the entire protein, thus leading to cumulative or even additive contributions to chimera thermostability. For this CBH II enzyme recombination, SCHEMA was effective in minimizing such broken contacts: whereas there are 303 total interblock contacts defined in the H. insolens parent CBH II crystal structure, the CBH II SCHEMA library design results in only 33 potential broken contacts. Given that the CBH II enzyme parents do not feature obvious structural subdomains, and only four of the eight blocks (1, 5, 7 and 8) resemble compact structural units, or modules, the low number of broken contacts demonstrates that the SCHEMA/RASPP algorithm is effective for cases in which the number of blocks appears greater than the number of structural subdivisions. As previously observed for β-lactamase and cytochrome P450 chimeras, low E values were predictive of chimera folding and activity. Although not used here, this relationship should be valuable for designing chimera sample sets that contain a high fraction of active members.
The disclosure also used chimera to determine if the pH stability could be improved in CBH II enzymes. Whereas the specific activity of H. jecorina CBH II declines sharply as pH increases above the optimum value of 5, HJPlus, created by substituting stabilizing blocks onto the most industrially relevant H. jecorina CBH II enzyme, retains significantly more activity at these higher pHs (FIG. 4). The thermostable 11113132 and 13311332 chimeras, and also the H. insolens and C. thermophilum CBH II cellulase parents, have even broader pH/activity profiles than HJPlus. The narrow pH/activity profile of H. jecorina CBH II has been attributed to the deprotonation of several carboxyl-carboxylate pairs, which destabilizes the protein above pH  ̃6. The substitution of parent 3 in block 7 in HJPlus changes aspartate 277 to histidine, eliminating the carboxyl-carboxylate pair between D277 and D316 (of block 8). Replacing D277 with the positively charged histidine may prevent destabilizing charge repulsion at nonacidic pH, allowing HJPlus to retain activity at higher pH than H. jecorina CBH II. The even broader pH/activity profiles of the remaining two thermostable chimeras and the H. insolens and C. thermophilum parent CBH II enzymes may be due to the absence of acidic residues at positions corresponding to the E57-E119 carboxyl-carboxylate pair of HJPlus and H. jecorina CBH II.
HJPlus exhibits both relatively high specific activity and high thermostability. FIG. 5 shows that these properties lead to good performance in long-time hydrolysis experiments: HJPlus hydrolyzed cellulose at temperatures 7-15° C. higher than the parent CBH II enzymes and also had a significantly increased long-time activity relative to all the parents at their temperature optima, bettering H. jecorina CBH II by a factor of 1.7. Given that the specific activity of the HJPlus chimera is less than that of the H. jecorina CBH II parent, this increased long-time activity can be attributed to the ability of the thermostable HJPlus to retain activity at optimal hydrolysis temperatures over longer reaction timer.
The other two thermostable chimeras shared HJPlus's broad temperature range. This observation supports a positive correlation between t1/2 at elevated temperature and maximum operating temperature, and suggests that many of the thermostable chimeras among the 6,561 CBH II chimera sequences will also be capable of degrading cellulose at elevated temperatures. While this ability to hydrolyze the amorphous PASC substrate at elevated temperatures bodes well for the potential utility of thermostable fungal CBH II chimeras, studies with more challenging crystalline substrates and substrates containing lignin will provide a more complete assessment of this novel CBH II enzyme family's relevance to biomass degradation applications.
The majority of biomass conversion processes use mixtures of fungal cellulases (primarily CBH II, cellobiohydrolase class I (CBH I), endoglucanases and β-glucosidase) to achieve high levels of cellulose hydrolysis. Generating a diverse group of thermostable CBH II enzyme chimeras is the first step in building an inventory of stable, highly active cellulases from which enzyme mixtures can be formulated and optimized for specific applications and feedstocks.
“Peptide segment” refers to a portion or fragment of a larger polypeptide or protein. A peptide segment need not on its own have functional activity, although in some instances, a peptide segment may correspond to a domain of a polypeptide wherein the domain has its own biological activity. A stability-associated peptide segment is a peptide segment found in a polypeptide that promotes stability, function, or folding compared to a related polypeptide lacking the peptide segment. A destabilizing-associated peptide segment is a peptide segment that is identified as causing a loss of stability, function or folding when present in a polypeptide.
“Fused,” “operably linked,” and “operably associated” are used interchangeably herein to broadly refer to a chemical or physical coupling of two otherwise distinct domains or peptide segments, wherein each domain or peptide segment when operably linked can provide a functional polypeptide having a desired activity. Domains or peptide segments can be connected through peptide linkers such that they are functional or can be fused through other intermediates or chemical bonds. For example, two domains can be part of the same coding sequence, wherein the polynucleotides are in frame such that the polynucleotide when transcribed encodes a single mRNA that when translated comprises both domains as a single polypeptide. Alternatively, both domains can be separately expressed as individual polypeptides and fused to one another using chemical methods. Typically, the coding domains will be linked “in-frame” either directly of separated by a peptide linker and encoded by a single polynucleotide. Various coding sequences for peptide linkers and peptide are known in the art.
“Polynucleotide” or “nucleic acid sequence” refers to a polymeric form of nucleotides. In some instances a polynucleotide refers to a sequence that is not immediately contiguous with either of the coding sequences with which it is immediately contiguous (one on the 5′ end and one on the 3′ end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA) independent of other sequences. The nucleotides of the disclosure can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. A polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. The term polynucleotide encompasses genomic DNA or RNA (depending upon the organism, i.e., RNA genome of viruses), as well as mRNA encoded by the genomic DNA, and cDNA.
“Nucleic acid segment,” “oligonucleotide segment” or “polynucleotide segment” refers to a portion of a larger polynucleotide molecule. The polynucleotide segment need not correspond to an encoded functional domain of a protein; however, in some instances the segment will encode a functional domain of a protein. A polynucleotide segment can be about 6 nucleotides or more in length (e.g., 6-20, 20-50, 50-100, 100-200, 200-300, 300-400 or more nucleotides in length). A stability-associated peptide segment can be encoded by a stability-associated polynucleotide segment, wherein the peptide segment promotes stability, function, or folding compared to a polypeptide lacking the peptide segment.
“Chimera” refers to a combination of at least two segments of at least two different parent proteins. As appreciated by one of skill in the art, the segments need not actually come from each of the parents, as it is the particular sequence that is relevant, and not the physical nucleic acids themselves. For example, a chimeric fungal class II cellobiohydrolases (CBH II cellulases) will have at least two segments from two different parent CBH II polypeptides. The two segments are connected so as to result in a new polypeptide having cellulase activity. In other words, a protein will not be a chimera if it has the identical sequence of either one of the full length parents. A chimeric polypeptide can comprise more than two segments from two different parent proteins. For example, there may be 2, 3, 4, 5-10, 10-20, or more parents for each final chimera or library of chimeras. The segment of each parent polypeptide can be very short or very long, the segments can range in length of contiguous amino acids from 1 to 90%, 95%, 98%, or 99% of the entire length of the protein. In one embodiment, the minimum length is 10 amino acids. In one embodiment, a single crossover point is defined for two parents. The crossover location defines where one parent's amino acid segment will stop and where the next parent's amino acid segment will start. Thus, a simple chimera would only have one crossover location where the segment before that crossover location would belong to one parent and the segment after that crossover location would belong to the second parent. In one embodiment, the chimera has more than one crossover location. For example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11-30, or more crossover locations. How these crossover locations are named and defined are both discussed below. In an embodiment where there are two crossover locations and two parents, there will be a first contiguous segment from a first parent, followed by a second contiguous segment from a second parent, followed by a third contiguous segment from the first parent. Contiguous is meant to denote that there is nothing of significance interrupting the segments. These contiguous segments are connected to form a contiguous amino acid sequence. For example, a CBH II chimera from Humicola insolens (hereinafter “1”) and H. jecori (hereinafter “2”), with two crossovers at 100 and 150, could have the first 100 amino acids from 1, followed by the next 50 from 2, followed by the remainder of the amino acids from 1, all connected in one contiguous amino acid chain. Alternatively, the CBH II chimera could have the first 100 amino acids from 2, the next 50 from 1 and the remainder followed by 2. As appreciated by one of skill in the art, variants of chimeras exist as well as the exact sequences. Thus, not 100% of each segment need be present in the final chimera if it is a variant chimera. The amount that may be altered, either through additional residues or removal or alteration of residues will be defined as the term variant is defined. Of course, as understood by one of skill in the art, the above discussion applies not only to amino acids but also nucleic acids which encode for the amino acids.
The disclosure describes in addition to specific variants, variants that can be used to generate CBH II chimeras. A directed SCHEMA recombination library was used to generate cellobiohydrolase enzymes based on a particularly well-studied member of this diverse enzyme family, and more particularly cellobiohydrolase II enzymes: H. insolens is parent “1” (SEQ ID NO:2), H. jecorina is parent “2” (SEQ ID NO:4) and C. thermophilum is parent “3” (SEQ ID NO:6). SCHEMA is a computational based method for predicting which fragments of homologous proteins can be recombined without affecting the structural integrity of the protein (see, e.g., Meyer et al., (2003) Protein Sci., 12:1686-1693). This computational approached identified seven recombination points in the CBH II parental proteins, thereby allowing the formation of a library of CBH II chimera polypeptides, where each polypeptide comprise eight segments. Chimeras with higher stability are identifiable by determining the additive contribution of each segment to the overall stability, either by use of linear regression of sequence-stability data, or by reliance on consensus analysis of the MSAs of folded versus unfolded proteins. SCHEMA recombination ensures that the chimeras retain biological function and exhibit high sequence diversity by conserving important functional residues while exchanging tolerant ones.
Thus, as illustrated by various embodiments herein, the disclosure provides CBH II polypeptides comprising a chimera of parental domains of which a parental strand or the resulting chimeic coding sequence may be modified to comprise a C→S substitution as described above. In some embodiments, the polypeptide comprises a chimera having a plurality of domains from N- to C-terminus from different parental CBH II proteins: (segment 1)-(segment 2)-(segment 3)-(segment 4)-(segment 5)-(segment 6)-(segment 7)-(segment 8);
wherein segment 1 comprises amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 2 is from about amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 3 is from about amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 4 is from about amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 5 is from about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 6 is from about amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 7 is from about amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); and segment 8 is from about amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”);
wherein: x1 is residue 43, 44, 45, 46, or 47 of SEQ ID NO:2, or residue 42, 43, 44, 45, or 46 of SEQ ID NO:4 or SEQ ID NO:6; x2 is residue 70, 71, 72, 73, or 74 of SEQ ID NO:2, or residue 68, 69, 70, 71, 72, 73, or 74 of SEQ ID NO:4 or SEQ ID NO:6; x3 is residue 113, 114, 115, 116, 117 or 118 of SEQ ID NO:2, or residue 110, 111, 112, 113, 114, 115, or 116 of SEQ ID NO:4 or SEQ ID NO:6; x4 is residue 153, 154, 155, 156, or 157 of SEQ ID NO:2, or residue 149, 150, 151, 152, 153, 154, 155 or 156 of SEQ ID NO:4 or SEQ ID NO:6; x5 is residue 220, 221, 222, 223, or 224 of SEQ ID NO:2, or residue 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO:4 or SEQ ID NO:6; x6 is residue 256, 257, 258, 259, 260 or 261 of SEQ ID NO:2, or residue 253, 254, 255, 256, 257, 258, 259 or 260 of SEQ ID NO:4 or SEQ ID NO:6; x7 is residue 312, 313, 314, 315 or 316 of SEQ ID NO:2, or residue 309, 310, 311, 312, 313, 314, 315 or 318 of SEQ ID NO:4 or SEQ ID NO:6; and x8 is an amino acid residue corresponding to the C-terminus of the polypeptide have the sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.
Using the foregoing domain references a number of chimeric structure were generated as set forth in Table 1. 1,588 CBH II chimera sequences with T50 values predicted to be greater than the measured T50 value of 64.8 C for the H. insolens parent CBH II.



















31313232
13132231
13212231
21113231
22112331
33211132
22223232
32123131


31323333
11221233
13331133
21133232
21222133
33211131
31213132
11221333


11212133
33123232
13232232
22221133
32333132
12311232
22223231
11211231


31313231
33123231
13232231
21133231
32333131
12321333
22322232
11231232


31333232
21311333
22121133
23211232
22132332
33231132
31213131
11231231


11232133
21331333
33223232
23221333
22132331
12311231
31312132
33123332


31333231
32213332
23111232
23211231
33313332
33231131
22322231
33123331


21323112
32213331
23121333
23231232
33313331
12331232
31312131
31321232


21323111
32312332
33223231
11311333
33333332
12331231
31233132
31321231


32113332
21211133
33322232
23231231
33333331
23122232
31233131
33122132


32113331
32312331
23111231
21122133
33213132
23122231
31332132
33122131


31223133
13321112
33322231
11331333
33213131
11113232
31332131
12123232


21111133
32233332
23131232
11211133
33312132
11123333
23321133
12123231


31322133
13321111
23131231
11231133
33312131
11113231
23222232
32121332


32133332
32233331
11323112
33113132
12313232
11133232
23222231
32121331


32133331
32332332
11323111
33113131
12323333
12221133
11213232
21323133


21131133
21231133
11111133
33133132
33233132
11133231
11223333
13122232


32112132
32332331
11131133
33133131
12313231
31111332
11213231
13122231


32112131
32121232
32221232
31321133
33233131
31111331
11312232
22113132


32132132
32121231
32221231
31222232
33332132
31131332
11322333
22113131


32132131
13313133
22313232
31222231
33332131
13211232
11312231
22133132


21321312
32212132
22323333
12123133
12333232
31131331
11233232
22133131


33112332
32212131
22313231
32111132
12333231
13221333
11233231
23113332


21321311
13333133
22333232
13113232
32311332
13211231
11332232
23113331


33112331
32232132
22333231
13123333
32311331
13231232
11332231
23133332


11223233
32232131
31122232
32111131
32331332
22212332
31211332
23133331


33132332
33212332
31122231
13113231
32331331
13231231
31211331
12212332


11322233
33212331
11321312
32131132
12223133
22212331
31231332
21311232


33132331
22123133
11321311
13133232
12322133
11122133
31231331
12212331


31211232
33232332
22223133
32131131
31113332
22232332
12112332
21321333


31221333
33232331
22322133
13133231
31113331
22232331
31323232
21311231


31211231
23113232
23213232
33111332
31133332
33321232
12112331
12232332


21313333
23123333
23223333
33111331
32211132
33321231
11222133
21331232


31231232
23113231
23213231
33131332
13213232
23323133
31323231
12232331


31231231
23133232
23312232
11321233
31133331
31213332
12132332
21331231


21221112
23133231
23322333
33131331
13223333
31213331
12132331
23112132


21333333
11121112
23312231
13122133
32211131
31312332
32123332
23112131


21221111
12311133
23233232
12111232
13213231
31312331
32123331
23132132


12112232
11121111
11313333
12121333
13312232
31233332
21121133
23132131


12122333
12212232
23233231
12111231
13322333
31233331
32122132
32223332


12112231
12222333
23332232
12131232
13312231
31332332
32122131
22111332


12132232
12212231
23332231
12131231
32231132
31332331
33122332
32223331


12132231
21321233
11221112
32313332
13233232
31121232
33122331
32322332


21213133
12331133
11333333
32313331
32231131
31121231
31221232
22111331


21312133
12232232
11221111
21311133
13233231
22321133
31221231
21221133


13323112
12232231
23222133
21212232
13332232
22222232
21313232
32322331


13323111
13311333
11213133
21222333
13332231
31212132
21323333
22131332


21233133
23122133
11312133
32333332
33211332
22222231
21313231
22131331


21332133
13331333
11233133
21212231
33211331
31212131
21333232
13323133


32123232
11113133
11332133
32333331
33231332
31232132
21333231
32222132


32123231
11133133
22211232
21331133
33231331
31232131
12122232
32222131


13111133
32223232
22221333
21232232
22122232
23311232
12122231
33311132


13131133
22111232
22211231
21232231
31112132
23321333
22113332
33311131


12321112
22121333
22231232
32213132
22122231
23311231
22113331
33222332


12321111
32223231
22231231
32213131
31112131
23331232
21223133
33222331


33122232
32322232
31323133
32312132
31132132
23331231
21322133
33331132


33122231
22111231
21112232
32312131
33323232
21123133
22133332
33331131


21211333
32322231
21122333
32233132
31132131
23221133
22133331
23123232


13321312
22131232
21112231
32233131
13222133
11311133
13121133
23123231


13321311
22131231
21132232
32332132
33323231
11212232
22112132
12321133


21231333
13211133
21132231
32332131
12211232
11222333
22112131
12222232


11123112
13231133
32113132
33213332
12221333
11212231
22132132
12222231


12313133
11323312
32113131
33213331
12211231
11331133
22132131
13311232


11123111
11323311
11211333
33312332
12231232
11232232
33313132
13321333


21323233
33321133
32133132
33312331
12231231
11232231
33313131
13311231


12333133
33222232
32133131
33233332
23121133
31223232
23112332
22213332


13313333
33222231
11231333
33233331
11112232
21111232
23112331
13331232


32212332
11111333
33113332
33332332
11122333
21121333
33333132
22213331


32212331
11131333
33113331
33332331
11112231
31223231
33333131
22312332


13221112
11223112
33133332
33121232
11132232
31322232
23132332
13331231


13333333
11223111
11323233
33121231
32321232
21111231
23132331
22312331


13221111
11322112
33133331
33212132
11132231
31322231
21211232
11123133


32232332
11322111
31311232
33212131
32321231
21131232
21221333
22233332


32232331
13321233
31321333
12213232
31123232
21131231
21211231
22233331


22113232
22213232
31311231
12223333
31123231
32122332
21231232
22332332


22123333
22223333
31331232
12213231
22323133
32122331
21231231
22332331


22113231
22213231
31331231
12312232
33221232
13123133
12323133
22121232


22133232
22312232
21321112
12322333
33221231
33111132
32311132
31111132


22133231
22322333
33112132
33232132
23313232
33111131
13313232
22121231


13213133
22312231
21321111
12312231
23323333
33131132
13323333
31111131


13312133
22233232
33112131
33232131
23313231
33131131
32311131
31131132


13233133
22233231
12113232
12233232
23333232
21213232
13313231
31131131


13332133
22332232
12123333
12233231
23333231
21223333
32222332
13221133


11121312
22332231
12113231
12332232
11321112
21213231
32222331
22212132


12311333
31121133
33132132
12332231
11321111
21312232
32331132
22212131


11121311
11221312
33132131
32211332
23223133
21322333
13333232
22232132


22122133
11221311
12133232
32211331
23322133
21312231
32331131
22232131


12331333
22222133
12133231
23123133
11313133
21233232
13333231
23212332


33323133
23311133
32111332
32231332
11333133
21233231
33311332
23212331


23112232
23212232
32111331
32231331
22311232
21332232
33311331
23232332


23122333
23222333
31221133
32323232
22321333
21332231
33331332
23232331


23112231
23212231
32131332
12222133
22311231
12121133
22123232
11111232


11113333
23331133
21313133
32323231
31212332
13111232
33331331
11121333


23132232
11213333
32131331
31112332
31212331
13121333
31113132
11111231


23132231
23232232
21333133
31112331
22331232
13111231
22123231
11131232


11133333
11312333
12122133
13311133
22331231
32313132
31113131
11131231


12211133
23232231
13112232
31132332
31232332
32313131
31133132
31313332


21221233
11233333
13122333
13212232
31232331
13131232
31133131
31313331


12231133
11332333
13112231
31132331
21113232
22112332
13223133
31333332


13211333
11121233
13132232
13222333
21123333
13131231
13322133
31333331


22131131
22331331
13111331
33323132
33321132
22121132
11311132
11321132


33223332
21113332
13131332
33323131
33321131
22121131
11311131
11321131


23111332
21113331
13131331
23122332
11111332
23121332
11222332
11323132


33223331
21133332
21212132
23122331
11111331
23121331
11222331
11323131


33322332
22211132
21212131
11113332
11131332
11111132
11331132
11321332


23111331
21133331
21232132
11113331
11131331
11111131
11331131
11321331


33322331
22211131
21232131
11133332
13321232
11131132
21121332
11221132


23131332
22231132
12313332
12211132
13321231
11131131
21121331
11221131


23131331
22231131
12313331
11133331
22223332
22323332
13123132
21321132


33222132
23211332
12333332
12211131
22223331
22323331
13123131
21321131


33222131
23211331
12333331
21221232
22322332
22223132
21223332
13321132


12223232
23231332
33121132
21221231
22322331
22223131
21223331
13321131


12223231
23231331
33121131
12231132
31121132
22322132
21322332
11121132


12322232
21112132
12213132
12231131
31121131
22322131
21322331
11121131


12322231
21112131
12213131
13211332
22222132
23223332
12121132
11323332


32221332
21132132
12312132
13211331
22222131
23223331
12121131
11323331


32221331
23323232
12312131
13231332
23311132
23322332
13121332
11223132


22313332
21132131
21223232
13231331
23311131
23322331
13121331
11223131


22313331
23323231
21223231
11112132
23222332
11313332
21222132
11322132


22333332
11323133
21322232
11112131
23222331
11313331
21222131
11322131


22333331
22321232
12233132
11132132
23331132
11333332
12323332
11221332


31122332
31311132
21322231
32321132
11213332
11333331
12323331
11221331


31122331
22321231
12233131
13323232
23331131
23222132
12223132
21323132


13321133
31311131
12332132
11132131
11213331
23222131
12223131
21323131


13222232
31222332
12332131
32321131
11312332
11213132
12322132
21321332


13222231
31222331
13213332
13323231
11312331
11213131
12322131
21321331


22213132
31331132
13213331
33321332
11233332
11312132
13223332
21221132


22213131
31331131
13312332
33321331
11233331
11312131
13223331
21221131


22312132
12113132
13312331
31123132
11332332
11233132
13322332
13323132


22312131
12113131
13233332
31123131
11332331
11233131
13322331
13323131


22233132
21123232
13233331
33221132
11121232
11332132
13222132
12321132


22233131
21123231
13332332
33221131
11121231
11332131
13222131
12321131


22332132
12133132
13332331
23313132
31323332
22221332
12221332
13321332


22332131
12133131
13121232
12321232
11212132
22221331
12221331
13321331


23213332
13113332
13121231
23313131
31323331
31323132
23121132
11123132


23213331
13113331
32323132
12321231
11212131
31323131
23121131
11123131


23312332
13133332
32323131
23333132
11232132
21122332
11122332
13221132


23312331
13133331
22122332
23333131
11232131
21122331
11122331
13221131


23233332
23221232
22122331
11123232
31223132
11211332
22323132
11121332


23233331
23221231
33323332
11123231
21111132
11211331
22323131
11121331


23332332
11311232
13212132
31121332
31223131
11231332
23323332
23321132


23332331
11321333
33323331
31121331
31322132
11231331
23323331
23321131


23121232
11311231
13212131
13221232
21111131
11323232
23223132
11223332


23121231
11331232
13232132
13221231
31322131
11323231
23223131
11223331


23212132
11331231
13232131
22311132
21131132
31321332
23322132
11322332


23212131
13112132
12211332
22311131
21131131
31321331
23322131
11322331


23232132
13112131
12211331
22222332
11223232
12123332
11313132
11222132


23232131
13132132
12231332
22222331
11223231
12123331
11313131
11222131


22211332
13132131
12231331
22331132
11322232
31221132
11333132
21121132


22211331
12111332
33223132
22331131
11322231
31221131
11333131
21121131


11121133
12111331
23111132
23311332
31221332
21313132
22321332
21323332


22231332
11221133
33223131
23311331
31221331
21313131
22321331
21323331


22231331
12131332
33322132
23331332
21313332
21333132
21123332
21223132


22323232
12131331
23111131
23331331
21313331
21333131
21123331
21223131


31313132
33123132
33322131
21113132
21333332
12122132
22221132
21322132


22323231
33123131
12323232
21113131
21333331
12122131
22221131
21322131


31313131
21212332
12323231
21133132
12122332
13122332
23221332
13121132


21112332
21212331
23131132
21133131
12122331
13122331
23221331
13121131


21112331
21232332
23131131
23211132
21213132
11221232
11311332
21221332


31333132
21232331
11112332
23211131
21213131
11221231
11311331
21221331


31333131
32121132
11112331
23231132
21312132
21311332
21122132
12323132


21132332
13123232
11132332
23231131
21312131
21311331
21122131
12323131


21132331
32121131
32321332
11212332
21233132
21331332
11331332
13323332


23223232
13123231
11132331
11212331
21233131
21331331
11331331
13323331


23223231
33121332
32321331
11232332
21332132
21211132
11211132
13223132


23322232
33121331
31123332
11232331
21332131
21211131
11211131
13223131


23322231
12213332
31123331
31223332
13111132
21231132
11231132
13322132


11313232
12213331
32221132
21111332
13111131
21231131
11231131
13322131


11323333
12312332
13223232
31223331
13131132
13313132
31321132
12321332


11313231
12312331
32221131
31322332
13131131
13313131
31321131
12321331


11333232
12233332
13223231
21111331
21211332
13333132
12123132
11123332


11333231
12233331
13322232
31322331
21211331
13333131
12123131
11123331


31311332
12332332
13322231
21131332
21231332
22123132
13123332
12221132


31311331
12332331
22313132
21131331
21231331
22123131
13123331
12221131


31331332
23113132
22313131
31222132
12313132
23123332
11321232
13221332


31331331
12121232
22333132
31222131
12313131
23123331
11321231
13221331


12113332
23113131
33221332
23321232
21323232
12311132
13122132
11122132


12113331
12121231
22333131
23321231
21323231
12311131
13122131
11122131


11223133
23133132
33221331
13113132
12333132
12222332
12121332
23323132


11322133
23133131
23313332
13113131
12333131
21321232
12121331
23323131


12133332
32323332
23313331
13133132
13313332
12222331
21311132
22321132


12133331
12212132
31122132
13133131
13313331
21321231
21311131
22321131


22221232
32323331
23333332
11321133
13333332
12331132
21222332
23321332


31211132
12212131
31122131
11222232
13333331
12331131
21222331
23321331


22221231
21321133
23333331
11222231
22123332
13311332
21331132
21123132


31211131
21222232
23213132
21213332
22123331
13311331
21331131
21123131


31231132
21222231
12221232
21213331
13213132
23122132
12223332
23221132


31231131
12232132
23213131
21312332
13213131
23122131
12223331
23221131


12112132
12232131
23312132
21312331
13312132
13331332
12322332


12112131
13212332
12221231
21233332
13312131
13331331
12322331


21122232
13212331
23312131
21233331
13233132
11113132
23123132


21122231
13232332
23233132
21332332
13233131
11113131
23123131


12132132
13232331
23233131
12111132
13332132
11133132
12222132


12132131
32223132
23332132
21332331
13332131
11133131
12222131


13112332
22111132
23332131
12111131
12311332
22121332
13311132


13112331
32223131
22311332
21121232
12311331
22121331
13311131


13132332
32322132
22311331
21121231
22122132
13211132
13222332


13132331
22111131
11122232
12131132
22122131
13211131
13222331


32123132
32322131
22331332
12131131
12331332
13231132
13331132


11211232
22131132
11122231
13111332
12331331
13231131
13331131









Referring to the table above, each digit refers to a domain of a chimeric CBH II polypeptide. The number denotes the parental strand the domain was derived from. For example, a chimeric CBH II chimeric polypeptide having the sequence 12111131, indicates that the polypeptide comprises a sequence from the N-terminus to the C-terminus of: amino acids from about 1 to x1 of SEQ ID NO:2 (“1”) linked to amino acids from about x1 to x2 of SEQ ID NO:4 (“2”) linked to amino acids from about x2 to about x3 of SEQ ID NO:2 linked to amino acids from about x3 to about x4 of SEQ ID NO:2 linked to amino acids from about x4 to about x5 of SEQ ID NO:2 linked to amino acids from about x5 to about x6 of SEQ ID NO:2 linked to amino acids from about x6 to x7 of SEQ ID NO:6 (“3”) linked to amino acids from about x7 to x8 (e.g., the C-terminus) of SEQ ID NO:2.

In some embodiments, the CBH II polypeptide has a chimeric segment structure selected from the group consisting of:















11113132, 21333331, 21311131, 22232132, 33133132, 33213332,



13333232, 12133333, 13231111, 11313121, 11332333, 12213111,



23311333, 13111313, 31311112, 23231222, 33123313, 22212231,



21223122, 21131311, 23233133, 31212111 and 32333113.










In some embodiments, the polypeptide has improved thermostability compared to a wild-type polypeptide of SEQ ID NO:2, 4, or 6. The activity of the polypeptide can be measured with any one or combination of substrates as described in the examples. As will be apparent to the skilled artisan, other compounds within the class of compounds exemplified by those discussed in the examples can be tested and used.
In some embodiments, the polypeptide can have various changes to the amino acid sequence with respect to a reference sequence. The changes can be a substitution, deletion, or insertion of one or more amino acids. Where the change is a substitution, the change can be a conservative, a non-conservative substitution, or a combination of conservative and non-conservative substitutions. For example, the chimera can comprises a C→S substitution at C314 of SEQ ID NO:2 or C311 of SEQ ID NO:4.
Thus, in some embodiments, the polypeptides can comprise a general structure from N-terminus to C-terminus: (segment 1)-(segment 2)-(segment 3)-(segment 4)-(segment 5)-(segment 6)-(segment 7)-(segment 8),
wherein segment 1 comprises amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having 1-10 conservative amino acid substitutions; segment 2 is from about amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 3 is from about amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 4 is from about amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 5 is from about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 6 is from about amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; segment 7 is from about amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions; and segment 8 is from about amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”) and having about 1-10 conservative amino acid substitutions;
wherein x1 is residue 43, 44, 45, 46, or 47 of SEQ ID NO:2, or residue 42, 43, 44, 45, or 46 of SEQ ID NO:4 or SEQ ID NO:6; x2 is residue 70, 71, 72, 73, or 74 of SEQ ID NO:2, or residue 68, 69, 70, 71, 72, 73, or 74 of SEQ ID NO:4 or SEQ ID NO:6; x3 is residue 113, 114, 115, 116, 117 or 118 of SEQ ID NO:2, or residue 110, 111, 112, 113, 114, 115, or 116 of SEQ ID NO:4 or SEQ ID NO:6; x4 is residue 153, 154, 155, 156, or 157 of SEQ ID NO:2, or residue 149, 150, 151, 152, 153, 154, 155 or 156 of SEQ ID NO:4 or SEQ ID NO:6; x5 is residue 220, 221, 222, 223, or 224 of SEQ ID NO:2, or residue 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO:4 or SEQ ID NO:6; x6 is residue 256, 257, 258, 259, 260 or 261 of SEQ ID NO:2, or residue 253, 254, 255, 256, 257, 258, 259 or 260 of SEQ ID NO:4 or SEQ ID NO:6; x7 is residue 312, 313, 314, 315 or 316 of SEQ ID NO:2, or residue 309, 310, 311, 312, 313, 314, 315 or 318 of SEQ ID NO:4 or SEQ ID NO:6; and x8 is an amino acid residue corresponding to the C-terminus of the polypeptide have the sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 and wherein the chimera has an algorithm as set forth in Table 1 and wherein the chimera comprises a C→S substitution corresponding to C314 of SEQ ID NO:2 or C311 of SEQ ID NO:4.
In some embodiments, the number of substitutions can be 2, 3, 4, 5, 6, 8, 9, or 10, or more amino acid substitutions (e.g., 10-20, 21-30, 31-40 and the like amino acid substitutions).
In some embodiments, the functional CBH II polypeptides can have cellulase activity along with increased thermostability, such as for a defined substrate discussed in the Examples, and also have a level of amino acid sequence identity to a reference cellobiohydrolase, or segments thereof. The reference enzyme or segment, can be that of a wild-type (e.g., naturally occurring) or an engineered enzyme. Thus, in some embodiments, the polypeptides of the disclosure can comprise a general structure from N-terminus to C-terminus:
wherein segment 1 comprises a sequence that is at least 50-100% identity to amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 2 comprises a sequence that is at least 50-100% identity to amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 3 comprises a sequence that is at least 50-100% identity to amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 4 comprises a sequence that is at least 50-100% identity to amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 5 comprises a sequence that is at least 50-100% identity to about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 6 comprises a sequence that is at least 50-100% identity to amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 7 comprises a sequence that is at least 50-100% identity to amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); and segment 8 comprises a sequence that is at least 50-100% identity to amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”);
wherein x1 is residue 43, 44, 45, 46, or 47 of SEQ ID NO:2, or residue 42, 43, 44, 45, or 46 of SEQ ID NO:4 or SEQ ID NO:6; x2 is residue 70, 71, 72, 73, or 74 of SEQ ID NO:2, or residue 68, 69, 70, 71, 72, 73, or 74 of SEQ ID NO:4 or SEQ ID NO:6; x3 is residue 113, 114, 115, 116, 117 or 118 of SEQ ID NO:2, or residue 110, 111, 112, 113, 114, 115, or 116 of SEQ ID NO:4 or SEQ ID NO:6; x4 is residue 153, 154, 155, 156, or 157 of SEQ ID NO:2, or residue 149, 150, 151, 152, 153, 154, 155 or 156 of SEQ ID NO:4 or SEQ ID NO:6; x5 is residue 220, 221, 222, 223, or 224 of SEQ ID NO:2, or residue 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO:4 or SEQ ID NO:6; x6 is residue 256, 257, 258, 259, 260 or 261 of SEQ ID NO:2, or residue 253, 254, 255, 256, 257, 258, 259 or 260 of SEQ ID NO:4 or SEQ ID NO:6; x7 is residue 312, 313, 314, 315 or 316 of SEQ ID NO:2, or residue 309, 310, 311, 312, 313, 314, 315 or 318 of SEQ ID NO:4 or SEQ ID NO:6; and x8 is an amino acid residue corresponding to the C-terminus of the polypeptide have the sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 and wherein the chimera has an algorithm as set forth in Table 1 and wherein the chimera comprises a C→S substitution corresponding to C314 of SEQ ID NO:2 or C311 of SEQ ID NO:4.
In some embodiments, each segment of the chimeric polypeptide can have at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% or more sequence identity as compared to the reference segment indicated for each of the (segment 1), (segment 2), (segment 3), (segment 4)-(segment 5), (segment 6), (segment 7), and (segment 8) of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
In some embodiments, the polypeptide variants can have improved thermostability compared to the enzyme activity of the wild-type polypeptide of SEQ ID NO:2, 4, or 6 and wherein the chimera comprises a C→S substitution corresponding to C314 of SEQ ID NO:2 or C311 of SEQ ID NO:4.
The chimeric enzymes described herein may be prepared in various forms, such as lysates, crude extracts, or isolated preparations. The polypeptides can be dissolved in suitable solutions; formulated as powders, such as an acetone powder (with or without stabilizers); or be prepared as lyophilizates. In some embodiments, the polypeptide can be an isolated polypeptide.
In some embodiments, the polypeptides can be in the form of arrays. The enzymes may be in a soluble form, for example, as solutions in the wells of mircotitre plates, or immobilized onto a substrate. The substrate can be a solid substrate or a porous substrate (e.g, membrane), which can be composed of organic polymers such as polystyrene, polyethylene, polypropylene, polyfluoroethylene, polyethyleneoxy, and polyacrylamide, as well as co-polymers and grafts thereof. A solid support can also be inorganic, such as glass, silica, controlled pore glass (CPG), reverse phase silica or metal, such as gold or platinum. The configuration of a substrate can be in the form of beads, spheres, particles, granules, a gel, a membrane or a surface. Surfaces can be planar, substantially planar, or non-planar. Solid supports can be porous or non-porous, and can have swelling or non-swelling characteristics. A solid support can be configured in the form of a well, depression, or other container, vessel, feature, or location. A plurality of supports can be configured on an array at various locations, addressable for robotic delivery of reagents, or by detection methods and/or instruments.
The disclosure also provides polynucleotides encoding the engineered CBH II polypeptides disclosed herein. The polynucleotides may be operatively linked to one or more heterologous regulatory or control sequences that control gene expression to create a recombinant polynucleotide capable of expressing the polypeptide. Expression constructs containing a heterologous polynucleotide encoding the CBH II chimera can be introduced into appropriate host cells to express the polypeptide.
Given the knowledge of specific sequences of the CBH II chimera enzymes (e.g., the segment structure of the chimeric CBH II), the polynucleotide sequences will be apparent form the amino acid sequence of the engineered CBH II chimera enzymes to one of skill in the art. The knowledge of the codons corresponding to various amino acids coupled with the knowledge of the amino acid sequence of the polypeptides allows those skilled in the art to make different polynucleotides encoding the polypeptides of the disclosure. Thus, the disclosure contemplates each and every possible variation of the polynucleotides that could be made by selecting combinations based on possible codon choices, and all such variations are to be considered specifically disclosed for any of the polypeptides described herein.
In some embodiments, the polynucleotides encode the polypeptides described herein but have about 80% or more sequence identity, about 85% or more sequence identity, about 90% or more sequence identity, about 91% or more sequence identity, about 92% or more sequence identity, about 93% or more sequence identity, about 94% or more sequence identity, about 95% or more sequence identity, about 96% or more sequence identity, about 97% or more sequence identity, about 98% or more sequence identity, or about 99% or more sequence identity at the nucleotide level to a reference polynucleotide encoding the CBH II variant of chimera polypeptides and having a C→S substitution as described above (e.g., wherein the polypeptide or chimera comprises a C→S substitution corresponding to C314 of SEQ ID NO:2 or C311 of SEQ ID NO:4).
In some embodiments, the isolated polynucleotides encoding the polypeptides may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the isolated polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides and nucleic acid sequences utilizing recombinant DNA methods are well known in the art. Guidance is provided in Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press; and Current Protocols in Molecular Biology, Ausubel. F. ed., Greene Pub. Associates, 1998, updates to 2007.
In some embodiments, the polynucleotides are operatively linked to control sequences for the expression of the polynucleotides and/or polypeptides. In some embodiments, the control sequence may be an appropriate promoter sequence, which can be obtained from genes encoding extracellular or intracellular polypeptides, either homologous or heterologous to the host cell. For bacterial host cells, suitable promoters for directing transcription of the nucleic acid constructs of the present disclosure, include the promoters obtained from the E. coli lac operon, Bacillus subtilis xylA and xylB genes, Bacillus megatarium xylose utilization genes (e.g., Rygus et al., (1991) Appl. Microbiol. Biotechnol. 35:594-599; Meinhardt et al., (1989) Appl. Microbiol. Biotechnol. 30:343-350), prokaryotic beta-lactamase gene (VIIIa-Kamaroff et al., (1978) Proc. Natl. Acad. Sci. USA 75: 3727-3731), as well as the tac promoter (DeBoer et al., (1983) Proc. Natl. Acad. Sci. USA 80: 21-25). Various suitable promoters are described in “Useful proteins from recombinant bacteria” in Scientific American, 1980, 242:74-94; and in Sambrook et al., supra.
In some embodiments, the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3′ terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used.
In some embodiments, the control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA that is important for translation by the host cell. The leader sequence is operably linked to the 5′ terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used.
In some embodiments, the control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5′ end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide. Alternatively, the 5′ end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Effective signal peptide coding regions for bacterial host cells can be the signal peptide coding regions obtained from the genes for Bacillus NClB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral proteases (nprT, nprS, nprM), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, (1993) Microbiol Rev 57: 109-137.
The disclosure is further directed to a recombinant expression vector comprising a polynucleotide encoding the engineered CBH II variant or chimera polypeptide, and one or more expression regulating regions such as a promoter and a terminator, a replication origin, etc., depending on the type of hosts into which they are to be introduced. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
The recombinant expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the polynucleotide sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.
The expression vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon, may be used.
In some embodiments, the expression vector of the disclosure contains one or more selectable markers, which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers, which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol (Example 1) or tetracycline resistance. Other useful markers will be apparent to the skilled artisan.
In another embodiment, the disclosure provides a host cell comprising a polynucleotide encoding the CBH II variant or chimera polypeptide, the polynucleotide being operatively linked to one or more control sequences for expression of the polypeptide in the host cell. Host cells for use in expressing the polypeptides encoded by the expression vectors of the disclosure are well known in the art and include, but are not limited to, bacterial cells, such as E. coli and Bacillus megaterium; eukaryotic cells, such as yeast cells, CHO cells and the like, insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, BHK, 293, and Bowes melanoma cells; and plant cells. Other suitable host cells will be apparent to the skilled artisan. Appropriate culture mediums and growth conditions for the above-described host cells are well known in the art.
The CBH II variant or chimera polypeptides of the disclosure can be made by using methods well known in the art. Polynucleotides can be synthesized by recombinant techniques, such as that provided in Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press; and Current Protocols in Molecular Biology, Ausubel. F. ed., Greene Pub. Associates, 1998, updates to 2007. Polynucleotides encoding the enzymes, or the primers for amplification can also be prepared by standard solid-phase methods, according to known synthetic methods, for example using phosphoramidite method described by Beaucage et al., (1981) Tet Lett 22:1859-69, or the method described by Matthes et al., (1984) EMBO J. 3:801-05, e.g., as it is typically practiced in automated synthetic methods. In addition, essentially any nucleic acid can be obtained from any of a variety of commercial sources, such as The Midland Certified Reagent Company, Midland, Tex., The Great American Gene Company, Ramona, Calif., ExpressGen Inc. Chicago, Ill., Operon Technologies Inc., Alameda, Calif., and many others.
Engineered enzymes expressed in a host cell can be recovered from the cells and or the culture medium using any one or more of the well known techniques for protein purification, including, among others, lysozyme treatment, sonication, filtration, salting-out, ultra-centrifugation, chromatography, and affinity separation (e.g., substrate bound antibodies). Suitable solutions for lysing and the high efficiency extraction of proteins from bacteria, such as E. coli, are commercially available under the trade name CelLytic BTM from Sigma-Aldrich of St. Louis Mo.
Chromatographic techniques for isolation of the polypeptides include, among others, reverse phase chromatography high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, and affinity chromatography. Conditions for purifying a particular enzyme will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, etc., and will be apparent to those having skill in the art.
Descriptions of SCHEMA directed recombination and synthesis of chimeric polypeptides are described in the examples herein, as well as in Otey et al., (2006), PLoS Biol. 4 (5):e112; Meyer et al., (2003) Protein Sci., 12:1686-1693; U.S. patent application Ser. No. 12/024,515, filed Feb. 1, 2008; and U.S. patent application Ser. No. 12/027,885, filed Feb. 7, 2008; such references incorporated herein by reference in their entirety.
As discussed above, the polypeptide can be used in a variety of applications, such as, among others, biofuel generation, cellulose breakdown and the like.
The following examples are meant to further explain, but not limited the foregoing disclosure or the appended claims.
EXAMPLES
CBH II expression plasmid construction. Parent and chimeric genes encoding CBH II enzymes were cloned into yeast expression vector YEp352/PGK91-1-αss (FIG. 6). DNA sequences encoding parent and chimeric CBH II catalytic domains were designed with S. cerevisiae codon bias using GeneDesigner software (DNA2.0) and synthesized by DNA2.0. The CBH II catalytic domain genes were digested with XhoI and KpnI, ligated into the vector between the XhoI and KpnI sites and transformed into E. coli XL-1 Blue (Stratagene). CBH II genes were sequenced using primers: CBH2L (5′-GCTGAACGTGTCATCGGTTAC-3′ (SEQ ID NO:9) and RSQ3080 (5′-GCAACACCTGGCAATTCCTTACC-3′ (SEQ ID NO:10)). C-terminal His6 parent and chimera CBH II constructs were made by amplifying the CBH II gene with forward primer CBH2LPCR (5′-GCTGAACGTGTCATCGTTACTTAG-3′ (SEQ ID NO:11)) and reverse primers complementary to the appropriate CBH II gene with His6 overhangs and stop codons. PCR products were ligated, transformed and sequenced as above.
CBH II enzyme expression in S. cerevisiae. S. cerevisiae strain YDR483W BY4742 (Matα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ΔKRE2, ATCC No. 401-4317) was made competent using the EZ Yeast II Transformation Kit (Zymo Research), transformed with plasmid DNA and plated on synthetic dropout-uracil agar. Colonies were picked into 5 mL overnight cultures of synthetic dextrose casamino acids (SDCAA) media (20 g/L dextrose, 6.7 g/L Difco yeast nitrogen base, 5 g/L Bacto casamino acids, 5.4 g/L Na2HPO4, 8.56 g/L NaH2PO4.H2O) supplemented with 20 ug/mL tryptophan and grown overnight at 30° C., 250 rpm. 5 mL cultures were expanded into 40 mL SDCAA in 250 mL Tunair flasks (Shelton Scientific) and shaken at 30° C., 250 rpm for 48 hours. Cultures were centrifuged, and supernatants were concentrated to 500 uL, using an Amicon ultrafiltration cell fitted with 30-kDa PES membrane, for use in t1/2 assays. Concentrated supernatants were brought to 1 mM phenylmethylsulfonylfluoride and 0.02% NaN3. His6-tagged CBH II proteins were purified using Ni-NTA spin columns (Qiagen) per the manufacturer's protocol and the proteins exchanged into 50 mM sodium acetate, pH 4.8, using Zeba-Spin desalting columns (Pierce). Purified protein concentration was determined using Pierce Coomassie Plus protein reagent with BSA as standard. SDS-PAGE analysis was performed by loading either 20 uL of concentrated culture supernatant or approximately 5 ug of purified CBH II enzyme onto a 7.5% Tris-HCl gel (Biorad) and staining with SimplyBlue safe stain (Invitrogen). CBH II supernatants or purified proteins were treated with EndoH (New England Biolabs) for 1 hr at 37° C. per the manufacturer's instructions. CBH II enzyme activity in concentrated yeast culture supernatants was measured by adding 37.5 uL concentrated culture supernatant to 37.5 uL PASC and incubating for 2 hr at 50° C. Reducing sugar equivalents formed were determined via Nelson-Somogyi assay as described below.
Half-life, specific activity, pH-activity and long-time cellulose hydrolysis measurements. Phosphoric acid swollen cellulose (PASC) was prepared. To enhance CBH II enzyme activity on the substrate, PASC was pre-incubated at a concentration of 10 g/L with 10 mg/mL A. niger endoglucanase (Sigma) in 50 mM sodium acetate, pH 4.8 for 1 hr at 37° C. Endoglucanase was inactivated by heating to 95° C. for 15 minutes, PASC was washed twice with 50 mM acetate buffer and resuspended at 10 g/L in deionzed water.
CBH II enzyme t1/2s were measured by adding concentrated CBH II expression culture supernatant to 50 mM sodium acetate, pH 4.8 at a concentration giving A520 of 0.5 as measured in the Nelson-Somogyi reducing sugar assay after incubation with treated PASC as described below. 37.5 uL CBH II enzyme/buffer mixtures were inactivated in a water bath at 63° C. After inactivation, 37.5 uL endoglucanase-treated PASC was added and hydrolysis was carried out for 2 hr at 50° C. Reaction supernatants were filtered through Multiscreen HTS plates (Millipore). Nelson-Somogyi assay log(A520) values, obtained using a SpectraMax microplate reader (Molecular Devices) corrected for background absorbance, were plotted versus time and CBH II enzyme half-lives obtained from linear regression using Microsoft Excel.
For specific activity measurements, purified CBH II enzyme was added to PASC to give a final reaction volume of 75 uL 25 mM sodium acetate, pH 4.8, with 5 g/L PASC and CBH II enzyme concentration of 3 mg enzyme/g PASC. Incubation proceeded for 2 hr in a 50° C. water bath and the reducing sugar concentration determined. For pH/activity profile measurements, purified CBH II enzyme was added at a concentration of 300 ug/g PASC in a 75 uL reaction volume. Reactions were buffered with 12.5 mM sodium citrate/12.5 mM sodium phosphate, run for 16 hr at 50° C. and reducing sugar determined. Long-time cellulose hydrolysis measurements were performed with 300 uL volumes of 1 g/L treated PASC in 100 mM sodium acetate, pH 4.8, 20 mM NaCl. Purified CBH II enzyme was added at 100 ug/g PASC and reactions carried out in water baths for 40 hr prior to reducing sugar determination.
Five candidate parent genes encoding CBH II enzymes were synthesized with S. cerevisiae codon bias. All five contained identical N-terminal coding sequences, where residues 1-89 correspond to the cellulose binding module (CBM), flexible linker region and the five N-terminal residues of the H. jecorina catalytic domain. Two of the candidate CBH II enzymes, from Humicola insolens and Chaetomium thermophilum, were secreted from S. cerevisiae at much higher levels than the other three, from Hypocrea jecorina, Phanerochaete chrysosporium and Talaromyces emersonii (FIG. 1). Because bands in the SDS-PAGE gel for the three weakly expressed candidate parents were difficult to discern, activity assays in which concentrated culture supernatants were incubated with phosphoric acid swollen cellulose (PASC) were performed to confirm the presence of active cellulase. The values for the reducing sugar formed, presented in FIG. 1, confirmed the presence of active CBH II in concentrated S. cerevisiae culture supernatants for all enzymes except T. emersonii CBH II. H. insolens and C. thermophilum sequences were chose to recombine with the most industrially relevant fungal CBH II enzyme, from H. jecorina. The respective sequence identities of the catalytic domains are 64% (1:2), 66% (2:3) and 82% (1:3), where H. insolens is parent 1, H. jecorina is parent 2 and C. thermophilum is parent 3. These respective catalytic domains contain 360, 358 and 359 amino acid residues.
Heterologous protein expression in the filamentous fungus H. jecorina, the organism most frequently used to produce cellulases for industrial applications, is much more arduous than in Saccharomyces cerevisiae. The observed secretion of H. jecorina CBH II from S. cerevisiae motivated the choice of this heterologous host. To minimize hyperglycosylation, which has been reported to reduce the activity of recombinant cellulases, the recombinant CBH II genes were expressed in a glycosylation-deficient dKRE2 S. cerevisiae strain. This strain is expected to attach smaller mannose oligomers to both N-linked and O-linked glycosylation sites than wild type strains, which more closely resembles the glycosylation of natively produced H. jecorina CBH II enzyme. SDS-PAGE gel analysis of the CBH II proteins, both with and without EndoH treatment to remove high-mannose structures, showed that EndoH treatment did not increase the electrophoretic mobility of the enzymes secreted from this strain, confirming the absence of the branched mannose moieties that wild type S. cerevisiae strains attach to glycosylation sites in the recombinant proteins.
The high resolution structure of H. insolens (pdb entry 1ocn) was used as a template for SCHEMA to identify contacts that could be broken upon recombination. RASPP returned four candidate libraries, each with <E> below 15. The candidate libraries all have lower <E> than previously constructed chimera libraries, suggesting that an acceptable fraction of folded, active chimeras could be obtained for a relatively high <m>. Chimera sequence diversity was maximized by selecting the block boundaries leading to the greatest <m>=50. The blocks for this design are illustrated in FIG. 2B and detailed in Table 2.







TABLE 2





ClustalW multiple sequence alignment for parent CBH II enzyme catalytic domains.


Blocks 2, 4, 6 and 8 are denoted by boxes and grey shading. Blocks 1, 3, 5 and 7 are not


shaded. (H. inso: SEQ ID NO: 2; H. Jeco: SEQ ID NO: 4 and C. Ther: SEQ ID NO: 6).




















The H. insolens CBH II catalytic domain has an α/β barrel structure in which the eight helices define the barrel perimeter and seven parallel β-sheets form the active site (FIG. 2A). Two extended loops form a roof over the active site, creating a tunnel through which the substrate cellulose chains pass during hydrolysis. Five of the seven block boundaries fall between elements of secondary structure, while block 4 begins and ends in the middle of consecutive α-helices (FIGS. 2A, 2B). The majority of interblock sidechain contacts occur between blocks that are adjacent in the primary structure (FIG. 2C).
A sample set of 48 chimera genes was designed as three sets of 16 chimeras having five blocks from one parent and three blocks from either one or both of the remaining two parents (Table 3); the sequences were selected to equalize the representation of each parent at each block position. The corresponding genes were synthesized and expressed.







TABLE 3







Sequences of sample set CBH II enzyme chimeras.










Inactive
Active







13121211
11332333



12122221
21131311



33332321
31212111



33321331
22232132



21322232
33213332



21112113
23233133



31121121
13231111



32312222
12213111



23223223
31311112



31313323
11113132



32121222
13111313



12121113
21311131



22133222
11313121



33222333
21223122



11131231
22212231



11112321
23231222



12111212
32333113



31222212
12133333



22322312
13333232



12222213
33123313



12221122
21333331



22212323
23311333



23222321
33133132



32333223



33331213










Twenty-three of the 48 sample set S. cerevisiae concentrated culture supernatants exhibited hydrolytic activity toward PASC. These results suggest that thousands of the 6,561 possible CBH II chimera sequences (see e.g., Table 1) encode active enzymes. The 23 active CBH II sample set chimeras show considerable sequence diversity, differing from the closest parental sequence and each other by at least 23 and 36 amino acid substitutions and as many as 54 and 123, respectively. Their average mutation level <m> is 36.
As Meyer et al. found correlations between E, m and the probability that a chimera is folded and active, analysis of whether similar correlations existed for the sample set CBH II chimeras was analyzed. The amount of CBH II enzyme activity in concentrated expression culture supernatants, as measured by assaying for activity on PASC, was correlated to the intensity of CBH II bands in SDS-PAGE gels (FIG. 1). As with the H. jecorina CBH II parent, activity could be detected for some CBH II chimeras with undetectable gel bands. There were no observations of CBH II chimeras presenting gel bands but lacking activity. The probability of a CBH II chimera being secreted in active form was inversely related to both E and m (FIG. 3).
Half-lives of thermal inactivation (t1/2) were measured at 63° C. for concentrated culture supernatants of the parent and active chimeric CBH II enzymes. The H. insolens, H. jecorina and C. thermophilum CBH II parent half-lives were 95, 2 and 25 minutes, respectively (Table 1). The active sample set chimeras exhibited a broad range of half-lives, from less than 1 minute to greater than 3,000. Five of the 23 active chimeras had half-lives greater than that of the most thermostable parent, H. insolens CBH II.
In attempting to construct a predictive quantitative model for CBH II chimera half-life, five different linear regression data modeling algorithms were used (Table 4). Each algorithm was used to construct a model relating the block compositions of each sample set CBH II chimera and the parents to the log(t1/2). These models produced thermostability weight values that quantified a block's contribution to log(t1/2). For all five modeling algorithms, this process was repeated 1,000 times, with two randomly selected sequences omitted from each calculation, so that each algorithm produced 1,000 weight values for each of the 24 blocks. The mean and standard deviation (SD) were calculated for each block's thermostability weight. The predictive accuracy of each model algorithm was assessed by measuring how well each model predicted the t1/2s of the two omitted sequences. The correlation between measured and predicted values for the 1,000 algorithm iterations is the model algorithm's cross-validation score. For all five models, the cross-validation scores (X-val) were less than or equal to 0.57 (Table 4), indicating that linear regression modeling could not be applied to this small, 23 chimera t1/2 data set for quantitative CBH II chimera half-life prediction.







TABLE 4







Cross validation values for application of 5 linear regression


algorithms to CBH II enzyme chimera block stability scores.














Method
Ridge
PLS
SVMR
LSVM
LPBoost







X-val
0.56
0.55
0.50
0.42
0.43







Algorithm abbreviations: ridge regression (RR), partial least square regression (PLSR), support vector machine regression (SVMR), linear programming support vector machine regression (LPSVMR) and linear programming boosting regression (LPBoostR).






Linear regression modeling was used to qualitatively classify blocks as stabilizing, destabilizing or neutral. Each block's impact on chimera thermostability was characterized using a scoring system that accounts for the thermostability contribution determined by each of the regression algorithms. For each algorithm, blocks with a thermostability weight value more than 1 SD above neutral were scored “+1”, blocks within 1 SD of neutral were assigned zero and blocks 1 or more SD below neutral were scored “−1”. A “stability score” for each block was obtained by summing the 1, 0, −1 stability scores from each of the five models. Table 5 summarizes the scores for each block. Block 1/parent 1 (B1P1), B6P3, B7P3 and B8P2 were identified as having the greatest stabilizing effects, while B1P3, B2P1, B3P2, B6P2, B7P1, B7P2 and B8P3 were found to be the most strongly destabilizing blocks.







TABLE 5







Qualitative block classification results generated by five linear


regression algorithms1 for sample set CBH II enzyme chimeras.













Block
Ridge
PLS
SVMR
LSVM
LPBoost
Sum
















B1P1
1
0
1
1
0
3


B1P2
0
0
0
−1
0
−1


B1P3
−1
0
−1
−1
−1
−4


B2P1
−1
0
0
−1
−1
−3


B2P2
1
0
0
0
0
1


B2P3
1
0
0
0
0
1


B3P1
1
0
1
0
0
2


B3P2
−1
0
−1
−1
−1
−4


B3P3
1
0
1
0
0
2


B4P1
0
0
0
0
0
0


B4P2
0
0
0
0
0
0


B4P3
0
0
0
−1
0
−1


B5P1
0
0
0
0
0
0


B5P2
0
0
0
0
−1
−1


B5P3
−1
0
0
−1
0
−2


B6P1
1
0
0
−1
−1
−1


B6P2
−1
0
−1
−1
−1
−4


B6P3
1
1
1
1
1
5


B7P1
−1
0
−1
−1
−1
−4


B7P2
−1
0
−1
−1
−1
−4


B7P3
1
0
1
1
1
4


B8P1
1
0
1
−1
0
1


B8P2
1
0
1
1
0
3


B8P3
−1
0
−1
−1
−1
−4





Score of +1 denotes a block with thermostability weight (dimensionless metric for contribution of a block to chimera thermostability) greater than one standard deviation above neutral (stabilizing), score of 0 denotes block with weight within one standard deviation of neutral and −1 denotes block with weight more than one standard deviation below neutral (destabilizing).






A second set of genes encoding CBH II enzyme chimeras was synthesized in order to validate the predicted stabilizing blocks and identify cellulases more thermostable than the most stable parent. The 24 chimeras included in this validation set (Table 6) were devoid of the seven blocks predicted to be most destabilizing and enriched in the four most stabilizing blocks, where representation was biased toward higher stability scores. Additionally, the “HJPlus” 12222332 chimera was constructed by substituting the predicted most stabilizing blocks into the H. jecorina CBH II enzyme (parent 2).







TABLE 6







Sequences of 24 validation set CBH II enzyme chimeras, nine


of which were expressed in active form.










Inactive
Active







12122132
12111131



12132332
12132331



12122331
12131331



12112132
12332331



13122332
13332331



13111132
13331332



13111332
13311331



13322332
13311332



22122132
22311331



22322132



22311332



23111332



23321131



23321332



23321331










Concentrated supernatants of S. cerevisiae expression cultures for nine of the 24 validation set chimeras, as well as the HJPlus chimera, showed activity toward PASC (Table 6). Of the 15 chimeras for which activity was not detected, nine contained block B4P2. Of the 16 chimeras containing B4P2 in the initial sample set, only one showed activity toward PASC. Summed over both chimera sets and HJPlus, just two of 26 chimeras featuring B4P2 were active, indicating that this particular block is highly detrimental to expression of active cellulase in S. cerevisiae. 
The stabilities of the 10 functional chimeric CBH II enzymes from the validation set were evaluated. Because the stable enzymes already had half-lives of more than 50 hours, residual hydrolytic activity toward PASC after a 12-hour thermal inactivation at 63° C. was used as the metric for preliminary evaluation. This 12-hour incubation produced a measurable decrease in the activity of the sample set's most thermostable chimera, 11113132, and completely inactivated the thermostable H. insolens parent CBH II. All ten of the functional validation set chimeras retained a greater fraction of their activities than the most stable parent, H. insolens CBH II.
The activities of selected thermostable chimeras using purified enzymes was analyzed. The parent CBH II enzymes and three thermostable chimeras, the most thermostable sample set chimera 11113132, the most thermostable validation set chimera 13311332 and the HJPlus chimera 12222332, were expressed with C-terminal His6 purification tags and purified. To minimize thermal inactivation of CBH II enzymes during the activity test, we used a shorter, two-hour incubation with the PASC substrate at 50° C., pH 4.8. As shown in Table 3, the parent and chimera CBH II specific activities were within a factor of four of the most active parent CBH II enzyme, from H. jecorina. The specific activity of HJPlus was greater than all other CBH II enzymes tested, except for H. jecorina CBH II.
The pH dependence of cellulase activity is also important, as a broad pH/activity profile would allow the use of a CBH II chimera under a wider range of potential cellulose hydrolysis conditions. H. jecorina CBH II has been observed to have optimal activity in the pH range 4 to 6, with activity markedly reduced outside these values.16 FIG. 4 shows that the H. insolens and C. thermophilum CBH II enzymes and all three purified thermostable CBH II chimeras have pH/activity profiles that are considerably broader than that of H. jecorina CBH II. Although Liu et al. report an optimal pH of 4 for C. thermophilum CBH II, the optimal pH of the recombinant enzyme here was near 7. Native H. insolens CBH II has a broad pH/activity profile, with maximum activity around pH 9 and approximately 60% of this maximal activity at pH 4. A similarly broad profile was observed for the recombinant enzyme. The HJPlus chimera has a much broader pH/activity profile than H. jecorina CBH II, showing a pH dependence similar to the other two parent CBH II enzymes.
Achieving activity at elevated temperature and retention of activity over extended time intervals are two primary motivations for engineering highly stable CBH II enzymes. The performance of thermostable CBH II chimeras in cellulose hydrolysis was tested across a range of temperatures over a 40-hour time interval. As shown in FIG. 5, all three thermostable chimeras were active on PASC at higher temperatures than the parent CBH II enzymes. The chimeras retained activity at 70° C., whereas the H. jecorina CBH II did not hydrolyze PASC above 57° C. and the stable H. insolens enzyme showed no hydrolysis above 63° C. The activity of HJPlus in long-time cellulose hydrolysis assays exceeded that of all the parents at their respective optimal temperatures.
The CBH II library has fewer potential disruptions for several reasons. In addition to the higher identity of the CBH II parent sequences, the barrel topology of the CBH II fold limits the number of long-range contacts that can be broken by recombination. Between-block contacts (heavy atoms within 4.5 Å) comprise only 27% (503/1831) of the total in a contact map derived from H. insolens structure 1ocn. When only counting contacts for which novel residue pairs are possible in chimeras, the inter-block total is reduced to 23% (68/294). Furthermore, most of these interactions are between residues on the protein surface, and the possibility of solvent screening further decreases the chances of dramatic disruptive residue-residue interactions (FIG. 14a). One exception, a buried interaction between positions 176 and 256, is illustrated in FIG. 14b. At this site, chimeras with B6P2 and either B5P1 or B5P3 pair Met173:Trp253 (larger amino acid than parental pairs Met176:Phe256 or Leu173:Trp253). Nevertheless, upon inspection of the parental crystallographic models, a steric clash at this position was deemed unlikely due to movement in the portion of the protein backbone which positions Trp253 and the intrinsic flexibility of Met side chains. Notably, one characterized chimera fits this pattern (13333232) and is more stable than the parents (67° C.), in accord with the regression model fit (68° C.).
Another mechanism by which coupling could arise, block structural divergence, does not depend on the presence of novel residue pairs at block interfaces. Instead, as parental sequences diverge, intrinsic block structures may diverge, hindering modular block transplants. In the case of the CBH II library, the high parent pair sequence identity values (82%, 66%, and 64%) suggest that only minor structure deviations are likely (<1 Å RMSD). This possibility can be evaluated by comparing crystallographic structures for H. insolens and H. jecorina CBH II (C. thermophilum CBH II lacks a crystal structure but is 82% identical to H. insolens). Aligning blocks from structures for each parent (1ocn and 1cb2), generates low alpha carbon RMSD values (0.5, 0.5, 0.6, 0.5, 0.3, 0.7, 0.3, and 0.4 Å RMSD). H. jecorina blocks superimposed onto H. insolens are illustrated in Supplemental FIG. 5c. To check for context-dependent effects an in silico structural recombination was performed, splicing each aligned block onto the opposing host structure. It is possible to construct non-clashing structural models (alpha carbons >3 Å apart) for all single-block substitution chimeras (e.g., 11112111 or 22122222), with the exception of a minor clash (2.65 Å) when using B7P2 (11111121) due to the Asn insertion between blocks 6 and 7 (FIG. 14D).
Further experiments were performed to determine the contributions of various blocks/segments to the chimera's stability and improved thermostability and/or pH stability. Parent and chimeric genes encoding CBH II enzymes were cloned into yeast expression vector YEp352/PGK91-1-αss and expression in synthetic dextrose casamino acids (SDCAA) media. For Avicel activity assays, yeast peptone dextrose (YPD) culture supernatants were brought to 1 mM phenylmethylsulfonylfluoride and 0.02% NaN3 and used without concentration. CBH II enzyme activity in concentrated SDCAA yeast culture supernatants was measured by adding dilutions of concentrated culture supernatant to 37.5 μL PASC and 225 μL 50 mM sodium acetate, pH 4.8 and incubating for 2 hr at 50° C. Reducing sugar equivalents formed were determined via Nelson-Somogyi assay.
CBH II enzyme T50 values were measured by adding concentrated CBH II SDCAA expression culture supernatant to 50 mM sodium acetate, pH 4.8 at a concentration giving A520 of 0.5 as measured in the Nelson-Somogyi reducing sugar assay after incubation with endoglucanase-treated PASC. 200 μL CBH II enzyme/buffer mixtures were incubated in a water bath at the temperature of interest for 10 minutes. After incubation, 37.5 μL endoglucanase-treated PASC and 62.5 μL of 50 mM sodium acetate were added, and hydrolysis was carried out for 2 hr at 50° C. The incubation temperature at which the enzyme lost one-half of its activity was determined by linear interpolation of the Nelson-Somogyi assay A520 values plotted versus temperature.
For long-time Avicel PH101 (Fluka) hydrolysis measurements, 0.3 μg of purified CBH II was incubated with 3 mg of Avicel in 270 μL of 50 mM sodium acetate, pH 4.8, in PCR tubes placed in a water bath for 16 hours. Tubes were cooled in a room temperature water bath for 10 minutes, centrifuged at 1000 g for 10 minutes and supernatants withdrawn for reducing sugar analysis.
For estimation of CBH II activity in YPD expression culture supernatants, supernatant volumes ranging from 2 mL to 40 mL were added to 800 μL of 33 mg/mL Avicel suspended in 50 mM sodium acetate, pH 4.8 in conical tubes. CBH IIs were allowed to bind Avicel at 4° C. for one hour, centrifuged at 2000 g for 2 minutes and washed twice with 50 mM sodium acetate, pH 4.8. After the second wash, CBH II-bound Avicel was resuspended in 2.75 mL of sodium acetate buffer, split into 270 μL aliquots and incubated at 50° C. for 2.5 hours. Centrifugation and supernatant reducing sugar analysis were carried out as above.
The Linear Regression package in Mathematica was used to fit CBH II chimera T50 data to a 17-parameter, block additive model and was also used for cross validation analysis. Block effects are reported relative to a parent 1 (H. insolens CBH II) reference state with 16 parameters representing substitution of each of the 8 blocks from parents 2 and 3.
Values of T50, defined here as the temperature at which an enzyme loses 50% of its activity during a ten-minute incubation, were determined for the three parent cellobiohydrolases, 33 active CBH II chimeras from prior experiments and 18 additional chimeras that qualitative stability modeling predicted to be among the most thermostable, i.e. containing none of the 7 predicted destabilizing blocks and either 3 or 4 of the 4 predicted stabilizing blocks. All 51 chimera sequences are listed in Table 8. Re-culturing and re-concentrating all of the predicted thermostable chimeras previously classified as not secreted allowed for the obtaining of sufficient amounts of 12112132, 13111132 and 13322332 CBH IIs for T50 determination. The complete set of T50 values for the chimeras and parent CBH IIs is provided in Table 8. The amino acid sequences for all these CBH IIs appear in Table 7. All 31 predicted thermostable chimeras tested have T50 values more than two degrees higher than that of the most thermostable parent enzyme (64.8° C.). The table also identifies the Cys residue in block/domain 7 that can be mutated to a Ser to provide increased thermostability. Accordingly, the disclosure provides polypeptide of any of the following sequences wherein the underlined/italicized/bold Cys is substituted with a Ser residue and wherein the resulting polypeptide has improved thermostability compared to a wild-type enzyme.








TABLE 7





Amino acid sequences for CBH II parent and chimera



catalytic domains shown in Table 8. Table also includes catalytic


domain for P. chrysosporium CBH II. All recombinant CBH IIs share


the N-terminal CBM and linker from the native H. jecorina CBH II,
















(SEQ ID NO: 8)









CSSVWGQCGGQNWSGPTCCASGSTCVYSNDYYSQCLPGAASSSSSTRAASTTSRVSPTTSRSSSATPP



PGSTTTRVPPVGSGTATYS.


 


Parent 1 (H. insolens)








(SEQ ID NO: 2)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAQFIVDQGRSGKQP


TGQKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAPE


AGQWFNEYFIQLLRNANPPF


 


Parent 2 (H. jecorina)








(SEQ ID NO: 4)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTANK



NGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDTIRQIVVEYSDIRTLLVIEPDSLAN


LVTNLGTPKCANAQSAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASSP


RALRGLATNVANYNGWNITSPPSYTQGNAVYNEKLYIHAIGPLLANHGWSNAFFITDQGRSGKQPTGQ


QQWGDWCNVIGTGFGIRPSANTGDSLLDSFVWVKPGGE DGTSDSSAPRFDSHCALPDALQPAPQAGA


WFQAYFVQLLTNANPSFL


 


Parent 3 (C. thermophilum)








(SEQ ID NO: 6)









GNPFSGVQLWANTYYSSEVHTLAIPSLSPELAAKAAKVAEVPSFQWLDRNVTVDTLFSGTLAEIRAAN



QRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDA


GRPAAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTSAARYDYHCGLSDALTPAPEA


GQWFQAYFEQLLINANPPF


 


P. chrysosporium CBH II








(SEQ ID NO: 12)









NNPWTGFQIFLSPYYANEVAAAAKQITDPTLSSKAASVANIPTFTWLDSVAKIPDLGTYLASASALGK



STGTKQLVQIVIYDLPDRDCAAKASNGEFSIANNGQANYENYIDQIVAQIQQFPDVRVVAVIEPDSLA


NLVTNLNVQKCANAKTTYLACVNYALTNLAKVGVYMYMDAGHAGWLGWPANLSPAAQLFTQVWQNAGK


SPFIKGLATNVANYNALQAASPDPITQGNPNYDEIHYINALAPLLQQAGWDATFIVDQGRSGVQNIRQ


QWGDWCNIKGAGFGTRPTTNTGSQFIDSIVWVKPGGE DGTSNSSSPRYDSTCSLPDAAQPAPEAGTW


FQAYFQTLVSAANPPL


 


32333113








(SEQ ID NO: 13)









GNPFSGVQLWANTYYSSEVHTLAIPSLSPELAAKAAKVAEVPSFMWLDTLDKTPLMEQTLADIRTANK



NGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDSL


ANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDAG


RPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAQFIVDQGRSGKQPTG


QKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTSAARYDYHCGLSDALTPAPEAG


QWFQAYFEQLLINANPPF


 


13111313








(SEQ ID NO: 14)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAQFIVDQGRSGKQP


TGQKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTSAARYDYHCGLSDALTPAPE


AGQWFQAYFEQLLINANPPF


 


11313121








(SEQ ID NO: 15)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRD


AGRPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPNAFFITDQGRSGKQ


PTGQQQWGDWCNVIGTGFGIRPSANTGDSLLDSFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAP


EAGQWFNEYFIQLLRNANPPF


 


21131311








(SEQ ID NO: 16)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFQWLDRNVTVDTLLVQTLSEIREAN



QAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAQFIVDQGRSGKQPT


GQKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


31212111








(SEQ ID NO: 17)









GNPFSGVQLWANTYYSSEVHTLAIPSLSPELAAKAAKVAEVPSFQWLDRNVTVDTLLVQTLSEIREAN



QAGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIREILISFSDVRTILVIEPDSLA


NMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASS


PRALRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAQFIVDQGRSGKQPTGQ


KEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAPEAGQ


WFNEYFIQLLRNANPPF


 


23233133








(SEQ ID NO: 18)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFQWLDRNVTVDTLFSGTLAEIRAAN



QRGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIRELLIQYSDIRTILVIEPDSLA


NMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDAGR


PAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPTGQ


LEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTSAARYDYHCGLSDALTPAPEAGQ


WFQAYFEQLLINANPPF


 


31311112








(SEQ ID NO: 19)









GNPFSGVQLWANTYYSSEVHTLAIPSLS_PELAAKAAKVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFP_AQFIVDQGRSGKQ


PTGQKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


22212231








(SEQ ID NO: 20)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTANK



NGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIREILISFSDVRTILVIEPDSLAN


MVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASSP


RALRGLATNVANYNGWNITSPPSYTQGNAVYNEKLYIHAIGPLLANHGWS_AKFIVDTGRNGKQPTGQ


LEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEAGQ


WFNEYFIQLLRNANPPF


 


13231111








(SEQ ID NO: 21)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIRELLIQYSDIRTILVIEPDSL


ANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDAG


KPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAQFIVDQGRSGKQPTG


QKEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAPEAG


QWFNEYFIQLLRNANPPF


 


12213111








(SEQ ID NO: 22)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIREILISFSDVRTILVIEPDSLA


NMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDAGR


PAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAQFIVDQGRSGKQPTGQ


KEWGHWCNAIGTGFGMRPTANTGHQYVDAFVWVKPGGE DGTSDTTAARYDYHCGLEDALKPAPEAGQ


WFNEYFIQLLRNANPPF


 


12133333








(SEQ ID NO: 23)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDA


GRPAAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTSAARYDYHCGLSDALTPAPEA


GQWFQAYFEQLLINANPPF


 


33133132








(SEQ ID NO: 24)









GNPFSGVQLWANTYYSSEVHTLAIPSLSPELAAKAAKVAEVPSFQWLDRNVTVDTLFSGTLAEIRAAN



QRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDA


GRPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


11332333








(SEQ ID NO: 25)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTSAARYDYHCGLSDALTPAPE


AGQWFQAYFEQLLINANPPF


 


23311333








(SEQ ID NO: 26)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFQWLDRNVTVDTLFSGTLAEIRAAN



QRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTSAARYDYHCGLSDALTPAPEA


GQWFQAYFEQLLINANPPF


 


33213332








(SEQ ID NO: 27)









GNPFSGVQLWANTYYSSEVHTLAIPSLSPELAAKAAKVAEVPSFQWLDRNVTVDTLFSGTLAEIRAAN



QRGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIREILISFSDVRTILVIEPDSLA


NMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDAGR


PAAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPTGQ


LEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQAGA


WFQAYFVQLLTNANPSFL


 


13333232








(SEQ ID NO: 28)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRD


AGRPAAVRGLATNVANYNGWNITSPPSYTQGNAVYNEKLYIHAIGPLLANHGWS_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


22232132








(SEQ ID NO: 29)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTANK



NGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDRIRELLIQYSDIRTILVIEPDSLAN


MVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASSP


RALRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPTGQL


EWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQAGAW


FQAYFVQLLTNANPSFL


 


11113132








(SEQ ID NO: 30)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRD


AGRPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


21333331








(SEQ ID NO: 31)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFQWLDRNVTVDTLLVQTLSEIREAN



QAGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDA


GRPAAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


21311131








(SEQ ID NO: 32)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFQWLDRNVTVDTLLVQTLSEIREAN



QAGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


12332331








(SEQ ID NO: 33)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNA


SSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


13112332








(SEQ ID NO: 34)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


22311331








(SEQ ID NO: 35)









GNPFVGVTPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTANK



NGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPDSL


ANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDAG


KPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPTG


QLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEAG


QWFNEYFIQLLRNANPPF


 


12111332








(SEQ ID NO: 36)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDT_LDKTPLMEQTLADIRTA



NKNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFD_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


12112332








(SEQ ID NO: 37)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDT_LDKTPLMEQTLADIRTA



NKNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFD_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


12131331








(SEQ ID NO: 38)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


12131332








(SEQ ID NO: 39)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


12332332








(SEQ ID NO: 40)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNA


SSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


12111131








(SEQ ID NO: 41)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


12311332








(SEQ ID NO: 42)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


13332331








(SEQ ID NO: 43)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPE


AGQWFNEYFIQLLRNANPPF


 


12132331








(SEQ ID NO: 44)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNA


SSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAPEA


GQWFNEYFIQLLRNANPPF


 


12132332








(SEQ ID NO: 45)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNA


SSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


13332332








(SEQ ID NO: 46)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


12112132








(SEQ ID NO: 47)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNA


SSPRALRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


13322332








(SEQ ID NO: 48)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDTIRQIVVEYSDIRTLLVIEPD


SLANLVTNLGTPKCANAQSAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


13131332








(SEQ ID NO: 49)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


12331332








(SEQ ID NO: 50)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPDS


LANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYEDA


GKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


13312332








(SEQ ID NO: 51)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


11113332








(SEQ ID NO: 52)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRD


AGRPAAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


13113132








(SEQ ID NO: 53)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRD


AGRPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


11112132








(SEQ ID NO: 54)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFP_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


12113132








(SEQ ID NO: 55)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPDS


LANMVTNMNVPKCSGAASTYKELTVYALKQLNLPHVAMYMDAGHAGWLGWPANIQPAAELFAQIYRDA


GRPAAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPT


GQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQA


GAWFQAYFVQLLTNANPSFL


 


13132332








(SEQ ID NO: 56)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKN


ASSPRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


11111132








(SEQ ID NO: 57)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLLVQTLSEIREA



NQAGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


13331332








(SEQ ID NO: 58)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIRELLIQYSDIRTILVIEPD


SLANMVTNMNVQKCSNAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


13111132








(SEQ ID NO: 59)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPQYAAQIVVYDLPDRDCAAAASNGEWAIANNGVNNYKAYINRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFP_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAP


QAGAWFQAYFVQLLTNANPSFL


 


12222132








(SEQ ID NO: 60)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDTIRQIVVEYSDIRTLLVIEPDSLA


NLVTNLGTPKCANAQSAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASS


PRALRGLATNVANYNAWSVSSPPPYTSPNPNYDEKHYIEAFRPLLEARGFPAKFIVDTGRNGKQPTGQ


LEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQAGA


WFQAYFVQLLTNANPSFL


 


12222332








(SEQ ID NO: 61)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFMWLDTLDKTPLMEQTLADIRTAN



KNGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDTIRQIVVEYSDIRTLLVIEPDSLA


NLVTNLGTPKCANAQSAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASS


PRALRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQPTGQ


LEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQAGA


WFQAYFVQLLTNANPSFL


 


13311332








(SEQ ID NO: 62)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFDAKFIVDTGRNGKQP


TGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDSSAPRFDSHCALPDALQPAPQ


AGAWFQAYFVQLLTNANPSFL


 


13311331








(SEQ ID NO: 63)









GNPFEGVQLWANNYYRSEVHTLAIPQITDPALRAAASAVAEVPSFQWLDRNVTVDTLFSGTLAEIRAA



NQRGANPPYAGIFVVYDLPDRDCAAAASNGEWSIANNGANNYKRYIDRIREILISFSDVRTILVIEPD


SLANMVTNMNVPKCSGAASTYRELTIYALKQLDLPHVAMYMDAGHAGWLGWPANIQPAAELFAKIYED


AGKPRAVRGLATNVANYNAWSIASPPSYTSPNPNYDEKHYIEAFAPLLRNQGFD_AKFIVDTGRNGKQ


PTGQLEWGHWCNVKGTGFGVRPTANTGHELVDAFVWVKPGGESDGTSDTTAARYDYHCGLEDALKPAP


EAGQWFNEYFIQLLRNANPPF
















TABLE 8







Two independent duplicate T50 values (° C.) for parent CBH IIs, 23 original


sample set CBH II chimeras and predicted thermostable CBH II chimeras.








Sample Set Chimeras & Parents
Predicted Thermostable Chimeras














Sequence
T50(1)
T50(2)
MeanT50
Sequence
T50(1)
T50(2)
MeanT50

















32333113
52
51
51.5
12332331
66.5
67
66.8


13111313
56
53.5
54.8
*13112332
67
67
67


11313121
55
55.5
55.3
22311331
68
68
68


21131311
57.5
57
57.3
*12111332
68
68
68


31212111
59
58
58.5
*12112332
68.5
67.5
68


Parent 2
60
58
59
12131331
68.5
69
68.8


23233133
61
61
61
*12131332
70
67.5
68.8


31311112
60
62
61
*12332332
69
69
69


22212231
63
61
62
12111131
70
68.5
69.3


13231111
63
6.5
63.3
12311332
70
69
69.5


12213111
63
63.5
63.3
13332331
70
69
69.5


Parent 3
63.5
64.5
64
12132331
70.5
69
69.8


12133333
64
64
64
*12132332
70.5
69
69.8


Parent 1
64
65.5
64.8
*13332332
69.5
70
69.8


33133132
65
66
65
12112132
71
68.5
69.8


11332333
64.5
66
65.3
13322332
71
68.5
69.8


23311333
65
66
65.5
*13131332
70
70
70


33213332
66
66
66
*12331332
71
69
70


13333232
67.5
67
67.3
*13312332
70
70
70


22232132
68
68
68
*11113332
69.5
70.5
70


11113132
71.5
71
71.3
*13113132
70.5
69.5
70


21333331
73.5
75.5
74.5
*11112132
70.5
70
70.3


21311131
75.5
75.5
75
*12113132
70.5
70.5
70.5






*13132332
69.5
71.5
70.5






*11111132
71
70.5
70.8






13331332
72
70
71






*13111132
72
69.5
71.3






*12222132
72.5
70
71.3






12222332
72
69.5
71.3






13311332
71
71.5
71.7






13311331
73.5
72.5
73





The 18 chimeras synthesized for this work are preceded by an asterisk.






Applying linear regression to the sequence-stability data resulted in a ten-parameter model that fit the observed T50 values with R2=0.88 (FIG. 8). To better estimate the predictive capacity of the regression model outside the training set, an eleven-fold cross-validation was performed resulting in a R2 of 0.57, where removal of two outliers, (11313121 and 22222222) increases the cross validation R2 to 0.76. The regression model model uses the most stable parent 1 (H. insolens) as the reference state T50 and includes nine additional terms having p values ≦0.1. The model parameters (Table 9) show that a single block, block 7 from parent 3 (B7P3), is by far the strongest contributor to chimera thermostability relative to H. insolens CBH II. This block from C. thermophilum CBH II contributes approximately 8.5° C. to the stability of chimeras that contain it. Two of the 8 remaining blocks with p values ≦0.1 were found to make smaller stability contributions, of 1.2° C. and 2.7° C., whereas the other six decrease stability.







TABLE 9







T50 linear regression model parameters and p-values. Parameter


values with p ≦ 0.1, used to calculate the regression fit line of


FIG. 1, appear in bold. Block effects are reported relative to a


parent 1 (H. insolens CBH II) reference state with 16 parameters


representing substitution of each of the 8 blocks from parents 2 and 3.












Parameter




Block
Value
p-value















Parent1
62.8
0.00



B12
−0.9
0.35



B13
−3.5
0.00



B22
−1.7
0.06



B23
−1.1
0.25



B32
0.5
0.68



B33
1.2
0.10



B42
2.7
0.05



B43
0.0
0.99



B52
−1.3
0.10



B53
−0.6
0.50



B62
−3.5
0.02



B63
−0.7
0.37



B72
−3.8
0.05



B73
8.5
0.00



B82
0.0
1.00



B83
−5.6
0.00










Alignment of the B7P1 and B7P3 sequences (FIG. 10) shows that block 7 differs at 10 out of 56 amino acid positions in the H. insolens and C. thermophilum enzymes. In the background of the chimera with the highest T50 value, 21311131, each residue in B7P3 (segment 7 of parent 3 (SEQ ID NO:6)) was individually mutated to the corresponding residue in B7P1 (segment 7 of parent 1 (SEQ ID NO:2)) and determined T50 values for each of the point mutants was obtained. A mutation, S313C, markedly altered the chimera's thermostability: this single mutation reduced the T50 of 21311131 by approximately 10° C. (FIG. 11).
To study the effect of the reverse mutation in different backgrounds, genes for the H. insolens and H. jecorina parent CBH IIs encoding the C313S substitution (C314S in H. insolens and C311S in H. jecorina) were constructed, expressed, and the enzymes' T50 values were determined. The stabilities of chimeras 11111131 and 22222232, in which the stabilizing B7P3 is substituted into the wildtype H. insolens and H. jecorina enzymes were also quantified. Both the B7P3 block substitution and the Cys-Ser point mutation markedly stabilized the parent CBH IIs; the largest effect was a  ̃8° C. increase in T50 for H. jecorina CBH II containing the C311S substitution (FIG. 12). The Cys-Ser mutation was also tested in two chimeras, 31311112 and 13231111, that did not contain B7P3 as well as in a homologous CBH II (from Phanerochaete chrysosporium) which was not in the recombination parent set. The P. chrysosporium CBH II catalytic domain is only 55-56% identical to the parent CBH II catalytic domains. All of these enzymes were stabilized by the Cys-Ser substitution; the P. chrysosporium CBH II was stabilized by a remarkable 10° C. (FIG. 13).
Eight of the thermostable CBH II chimeras and the parent enzymes containing the equivalent C313S mutation were His6-tagged and purified so that their specific activities could be determined. As shown in Table 10A, the specific activities, as measured on amorphous cellulose (PASC) at 50° C., for these chimeras and native enzymes containing the Cys-Ser mutation are similar to those of the wildtype parents. Thus the increased thermostability does not come at the expense of specific activity.







TABLE 10A







Specific activity values (μg glucose reducing sugar equivalent/(μg CBH II


enzyme × min × 102)) for native, point mutant and selected


thermostable chimeric CBH IIs. Error bars show standard errors, where


standard error is defined as standard dev/sqrt (n), for three replicates.


2-hr reaction, 3 mg enzyme/g PASC, 50° C., 25 mM sodium


acetate, pH 4.8.











Specific Activity




μg Reducing Sugar/



CBH II Enzyme
(μg Enzyme × min) × 102







Humicola insolens (Parent 1)
5.3 +/− 0.5



Hypocrea jecorina (Parent 2)
8.4 +/− 0.4



Chaetomium thermophilum
4.8 +/− 0.3



(Parent 3)



Phanerochaete chyrsosporium
7.7 +/− 0.3



Humicola insolens C314S
5.3 +/− 0.9



Hypocrea jecorina C311S
7.8 +/− 0.5



Phanerochaete chyrsosporium
8.5 +/− 0.1



C311S



HJPlus (Chimera 12222332)
9.6 +/− 0.8



Chimera 13111132
8.5 +/− 0.3



Chimera 22222232
7.7 +/− 0.3



Chimera 13311332
6.8 +/− 0.6



Chimera 13311331
6.2 +/− 0.3



Chimera 11111131
6.1 +/− 0.9



Chimera 13112332
5.6 +/− 0.4



Chimera 21311131
5.5 +/− 0.3



Chimera 11113132
5.3 +/− 0.5



Chimera 21333331
3.8 +/− 0.4

















TABLE 10B







total activity in both synthetic (SDCAA) and rich (YPD) expression


culture media supernatants for H. jecorina and H. insolens wild


type, C313S point mutant and B7P3 block susbstitution CBH IIs.














SDCAA
SDCAA
SDCAA
YPD
YPD
YPD


CBH II
(1)
(2)
Mean
(1)
(2)
Mean
















H. jecorina
19
17
18
0.4
0.4
0.4


H. jeco C311S
50
43
47
6.1
5.5
5.9


H. jeco B7P3
35
33
34
3.9
3.6
3.8


H. insolens
73
83
78
6.2
6.0
6.1


H. inso C314S
100
97
98
8.8
8.0
8.4


H. inso B7P3
39
42
40
4.4
4.1
4.2





Values presented are μg glucose/mL cellulase activity assay per mL of expression culture supernatant CBH II equivalent added to cellulase activity assay. For SDCAA cultures, concentrated SDCAA culture supernatants were used and activity toward phosphoric acid swollen cellulose (1 mg/mL) at 50° C. for 100 minutes in 50 mM sodium acetate, pH 4.8, was measured. YPD supernatant CBH II was concentrated by binding to avicel and activity toward avicel (15 mg/mL) at 55° C. for 150 minutes in 50 mM sodium acetate, pH 4.8, was measured.






These same eight thermostable chimeras (T50 2-10° C. higher than the most stable parent) were then tested for activity on crystalline cellulose during a 16-hour incubation over a range of temperatures, including temperatures where the parent enzymes exhibit little or no activity. FIG. 9a shows that 7 of 8 tested thermostable chimeras were maximally active toward Avicel at 60-65° C., with all 8 chimeras retaining activity at 70° C., the highest temperature tested. In contrast, the three parent CBH IIs show maximum activity at 50° C. and are either completely or almost completely inactive at 70° C. Additionally, the seven chimeras with increased optimum activity temperatures hydrolyze significantly more Avicel than any of the parent CBH II enzymes. As shown in FIG. 9b, similar behaviors are observed for the H. insolens and H. jecorina parents containing the Cys-Ser point mutation. The Cys-Ser point mutation also increased the Avicel hydrolysis and maximum operating temperature for the P. chrysosporium CBH II. The P3B7 block substitution, which was made in the H. insolens and H. jecorina parents, increased both the operating temperature and hydrolysis of the H. insolens CBH II but, despite increasing maximum operating temperature, did not improve overall cellulose hydrolysis by the H. jecorina enzyme.
Low (<1 mg/L) secretion of wildtype H. jecorina CBH II was observed from the heterologous S. cerevisiae expression host. The C311S mutation in the wildtype H. jecorina CBH II enzyme markedly increases total secreted CBH II activity (Table 11). In synthetic (SDCAA) medium, the C311S and B7P3 substitutions increase H. jecorina CBH II total secreted activity by a factor of two, while in rich (YPD) medium the activity increase is tenfold. For the H. insolens CBH II parent, which is expressed at much higher levels than the other two parent CBH IIs, the C314S mutation increased secreted activity by a factor of  ̃1.5 whereas the B7P3 block substitution decreased it. Because the H. insolens and H. jecorina wildtype and Cys-Ser mutants all have similar specific activities (Table 10), the increase in total secreted cellulase activity is the result of improved secretion of the functional enzyme. A correlation between S. cerevisiae heterologous protein secretion and protein stability has been observed, suggesting that the increased secretion of the Cys-Ser mutant CBH IIs might reflect their higher stabilities.







TABLE 11







Specific activity values (μg glucose reducing sugar equivalent/(μg CBH II


enzyme × min × 102)) for native, point mutant and selected


thermostable chimeric CBH IIs. Error bars show standard errors, where


standard error is defined as standard dev/sqrt (n), for three replicates.


2-hr reaction, 3 mg enzyme/g PASC, 50° C., 25 mM sodium


acetate, pH 4.8.









Specific Activity



μg Reducing Sugar/


CBH II Enzyme
(μg Enzyme × min) × 102





Humicola insolens (Parent 1)
5.3 +/− 0.5


Hypocrea jecorina (Parent 2)
8.4 +/− 0.4


Chaetomium thermophilum (Parent 3)
4.8 +/− 0.3


Phanerochaete chyrsosporium
7.7 +/− 0.3


Humicola insolens C314S
5.3 +/− 0.9


Hypocrea jecorina C311S
7.8 +/− 0.5


Phanerochaete chyrsosporium C311S
8.5 +/− 0.1


HJPlus (Chimera 12222332)
9.6 +/− 0.8


Chimera 13111132
8.5 +/− 0.3


Chimera 22222232
7.7 +/− 0.3


Chimera 13311332
6.8 +/− 0.6


Chimera 13311331
6.2 +/− 0.3


Chimera 11111131
6.1 +/− 0.9


Chimera 13112332
5.6 +/− 0.4


Chimera 21311131
5.5 +/− 0.3


Chimera 11113132
5.3 +/− 0.5


Chimera 21333331
3.8 +/− 0.4









To model the Cys-Ser mutation, the high-resolution H. insolens CBH II 1ocn crystal structure was used. First, the hydrogen bond network was optimized with REDUCE. Cys314 was predicted to form a hydrogen bond to the carbonyl of Pro 339. To confirm this prediction, sidechain packing was optimized using the modeling platform SHARPEN. Ser314 is predicted to make the similar interactions to Cys314, resulting in stronger hydrogen bonding and a more favorable geometry (FIG. 14).
A number of effects might explain why the Cys-Ser mutation stabilizes a broad range of CBH IIs, including native CBH IIs and chimeras. Cys and Ser are similar (though not isosteric), and these two amino acids dominate sequence alignments at this position compared to other alternatives. The hydrogen bonding partners for this residue are backbone elements (the amide of Gly316 and the carbonyl of Pro339 and are therefore less likely to be dependent on third-party amino acid variations. Furthermore, the immediate neighboring side chains for this pocket (Asn283, Pro339, Phe345) are conserved among all four native CBH II cellulases studied.
The high-resolution (1.3 Å) H. insolens crystal structure (pdb entry 1ocn6) shows that Cys314 is part of a hydrogen bonding network (FIG. 15). The increased hydrogen bonding capacity of Ser relative to Cys may suggest a role for stronger hydrogen bonding interactions in the stabilization. The crystal structure also suggests that Ser may be preferred for steric reasons. Specifically, when the Cys side chain is rebuilt with canonical bond angles, a 6° bend is removed and Cys is pushed closer to the carbonyl of Pro339, creating an unfavorable steric interaction.
An alignment of the 196 protein sequences sharing the greatest identity to the H. jecorina CBH II. Fifty-four of the 250 most identical sequences were excluded from the alignment due to redundancy (i.e. point mutants for structural studies or >95% identical isoforms). There is a bias in favor of Ser311: 158 sequences have Ser, 20 have Ala, 10 have Cys, 5 have a deletion, and 3 have Gly. However, there are 42 other positions where the most frequent choice occurs with greater than twice the frequency of the H. jecorina amino acid.
The large stabilizing effect of the Cys-Ser mutation raises the possibility that Ser at this position is a global indicator of native cellulase thermostability. However, the T50 of 64.8° C. for H. insolens CBH II, which features Cys at this position, is greater than that of the C. thermophilum CBH II (64.0° C.), indicating that Ser is not the only stability determinant.
Thermostability is not the only property of interest for industrial cellulases. Specific activity, changes to cellulose binding, and effects on expression and product inhibition are all important as well. The chimeras and data herein demonstrate that recombination yields CBH II chimeras whose improved thermostability comes without cost to specific activity measured in short-time (e.g., 2-hour) cellulose hydrolysis assays. Similar observations were made for CBH IIs containing the thermostabilizing Cys-Ser mutation. In long-time hydrolysis assays, several of the CBH II chimeras and all three tested Cys-Ser mutant CBH IIs hydrolyzed more cellulose than the native CBH IIs. This superior performance is likely the result of having specific activity comparable to that of the parent CBH IIs along with greater thermostability that allows the enzyme to continue to function for longer time at the elevated temperatures. Because these assays were carried out with equal amounts of purified parent, chimera and Cys-Ser mutant enzymes, the observed high temperature hydrolysis improvements are not the result of increased secretion from the S. cerevisiae expression host. The thermostable chimeras and the Cys-Ser mutants may therefore prove to be useful components of enzyme formulations for cellulose degradation.
While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

## Claims

1. A recombinant variant of a parent cellulase comprising the sequence of SEQ ID NO:2, 4, 12, or 64-66 wherein the residue corresponding to position 311 of SEQ ID NO:4 is substituted with serine in said variant, wherein the variant has cellulase activity and increased thermostability compared to the parent cellulase lacking a serine at the same position.

2. A recombinant polypeptide comprising a sequence that (i) is between 95% to 99% identical to SEQ ID NO:13 comprising a C312S; (ii) is between 95% to 100% identical to SEQ ID NO:14 comprising a C314S; (iii) is between 95% to 100% identical to SEQ ID NO:15 comprising a C315S; (vi) is between 95% to 100% identical to SEQ ID NO:16 comprising a C313S; (v) is between 95% to 100% identical to SEQ ID NO:17 comprising a C311S; (vi) is between 95% to 100% identical to SEQ ID NO:19 comprising a C313S; (vii) is between 95% to 100% identical to SEQ ID NO:21 comprising a C312S; or (viii) is between 95% to 100% identical to SEQ ID NO:22 comprising a C31 S wherein the foregoing polypeptides have cellulase activity and improved thermostability compared to their corresponding parental (wild-type) protein lacking a Cys→Ser mutation.

3. A recombinant polypeptide, comprising a sequence selected from the group consisting of:
(a) a polypeptide having greater than 97% identity to a sequence selected from the group consisting of: (i) SEQ ID NO:13 and having a Ser at position 312, (ii) SEQ ID NO:14 and having a Ser at position 314, (iii) SEQ ID NO:15 and having a Ser at position 315, (iv) SEQ ID NO:16 and having a Ser at position 313 (v) SEQ ID NO:17 and having a Ser at position 311, (vi) SEQ ID NO:19 and having a Ser at position 313, (vii) SEQ ID NO:21 and having a Ser at position 312, and (viii) SEQ ID NO:22 and having a Ser at position 311, and wherein each of the foregoing polypeptides have cellulase activity; and
(b) a chimeric polypeptide comprising at least two domains from two different parental cellobiohydrolase polypeptides, wherein the domains comprise from N- to C-terminus: (segment 1)-(segment 2)-(segment 3)-(segment 4)-(segment 5)-(segment 6)-(segment 7)-(segment 8); wherein:
segment 1 comprises a sequence that is at least 95-100% identical to amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 2 comprises a sequence that is at least 95-100% identical to amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 3 comprises a sequence that is at least 95-100% identical to amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 4 comprises a sequence that is at least 95-100% identical to amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 5 comprises a sequence that is at least 95-100% identical to about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 6 comprises a sequence that is at least 95-100% identical to amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 7 comprises a sequence that is at least 95-100% identical to amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); and segment 8 comprises a sequence that is at least 95-100% identical to amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”);
wherein x1 is residue 43, 44, 45, 46, or 47 of SEQ ID NO:2, or residue 42, 43, 44, 45, or 46 of SEQ ID NO:4 or SEQ ID NO:6; x2 is residue 70, 71, 72, 73, or 74 of SEQ ID NO:2, or residue 68, 69, 70, 71, 72, 73, or 74 of SEQ ID NO:4 or SEQ ID NO:6; x3 is residue 113, 114, 115, 116, 117 or 118 of SEQ ID NO:2, or residue 110, 111, 112, 113, 114, 115, or 116 of SEQ ID NO:4 or SEQ ID NO:6; x4 is residue 153, 154, 155, 156, or 157 of SEQ ID NO:2, or residue 149, 150, 151, 152, 153, 154, 155 or 156 of SEQ ID NO:4 or SEQ ID NO:6; x5 is residue 220, 221, 222, 223, or 224 of SEQ ID NO:2, or residue 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO:4 or SEQ ID NO:6; x6 is residue 256, 257, 258, 259, 260 or 261 of SEQ ID NO:2, or residue 253, 254, 255, 256, 257, 258, 259 or 260 of SEQ ID NO:4 or SEQ ID NO:6; X7 is residue 312, 313, 314, 315 or 316 of SEQ ID NO:2, or residue 309, 310, 311, 312, 313, 314, 315 or 318 of SEQ ID NO:4 or SEQ ID NO:6; and x8 is an amino acid residue corresponding to the C-terminus of the polypeptide have the sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6,
wherein the chimeric polypeptide comprises a Ser at position corresponding to position 314 of SEQ ID NO:2 or position 311 of SEQ ID NO:4 and wherein the chimeric polypeptide has cellulase activity and improved thermostability and/or pH stability compared to a CBH II polypeptide comprising SEQ ID NO:2, 4, or 6.

4. The recombinant polypeptide of claim 3, wherein segment 1 comprises amino acid residue from about 1 to about x1 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 2 is from about amino acid residue x1 to about x2 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 3 is from about amino acid residue x2 to about x3 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 4 is from about amino acid residue x3 to about x4 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 5 is from about amino acid residue x4 to about x5 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 6 is from about amino acid residue x5 to about x6 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); segment 7 is from about amino acid residue x6 to about x7 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”); and segment 8 is from about amino acid residue x7 to about x8 of SEQ ID NO:2 (“1”), SEQ ID NO:4 (“2”) or SEQ ID NO:6 (“3”).

5. An enzymatic preparation comprising a polypeptide of claim 1, 2 or 3.

6. A method of treating a biomass comprising cellulose, the method comprising contacting the biomass with a polypeptide of claim 1, 2 or 3.

7. A method of treating a biomass comprising cellulose, the method comprising contacting the biomass with an enzymatic preparation of claim 5.